US3732865A - Osmotic dispenser - Google Patents
Osmotic dispenser Download PDFInfo
- Publication number
- US3732865A US3732865A US00106130A US3732865DA US3732865A US 3732865 A US3732865 A US 3732865A US 00106130 A US00106130 A US 00106130A US 3732865D A US3732865D A US 3732865DA US 3732865 A US3732865 A US 3732865A
- Authority
- US
- United States
- Prior art keywords
- dispenser
- compartment
- active agent
- osmotic
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003204 osmotic effect Effects 0.000 title claims abstract description 76
- 239000013543 active substance Substances 0.000 claims abstract description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000002775 capsule Substances 0.000 claims abstract description 17
- 239000012528 membrane Substances 0.000 claims description 63
- 229940079593 drug Drugs 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 39
- 229920002301 cellulose acetate Polymers 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000012266 salt solution Substances 0.000 claims description 6
- 235000002639 sodium chloride Nutrition 0.000 claims description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- 244000043261 Hevea brasiliensis Species 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 3
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 3
- 239000001527 calcium lactate Substances 0.000 claims description 3
- 235000011086 calcium lactate Nutrition 0.000 claims description 3
- 229960002401 calcium lactate Drugs 0.000 claims description 3
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 235000011147 magnesium chloride Nutrition 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 229920003052 natural elastomer Polymers 0.000 claims description 3
- 229920001194 natural rubber Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 3
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 claims description 3
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 3
- 239000001120 potassium sulphate Substances 0.000 claims description 3
- 235000011151 potassium sulphates Nutrition 0.000 claims description 3
- 229920002379 silicone rubber Polymers 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- 235000010265 sodium sulphite Nutrition 0.000 claims description 3
- OKUCEQDKBKYEJY-UHFFFAOYSA-N tert-butyl 3-(methylamino)pyrrolidine-1-carboxylate Chemical compound CNC1CCN(C(=O)OC(C)(C)C)C1 OKUCEQDKBKYEJY-UHFFFAOYSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
- 239000004945 silicone rubber Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 230000004888 barrier function Effects 0.000 abstract description 22
- 239000000463 material Substances 0.000 abstract description 16
- 230000002035 prolonged effect Effects 0.000 abstract description 11
- 230000035699 permeability Effects 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 230000003467 diminishing effect Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- -1 fertility promoters Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 231100000344 non-irritating Toxicity 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000001223 reverse osmosis Methods 0.000 description 4
- 210000004767 rumen Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 230000002009 allergenic effect Effects 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000005266 casting Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000010612 desalination reaction Methods 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000005060 rubber Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- GIKNHHRFLCDOEU-UHFFFAOYSA-N 4-(2-aminopropyl)phenol Chemical compound CC(N)CC1=CC=C(O)C=C1 GIKNHHRFLCDOEU-UHFFFAOYSA-N 0.000 description 2
- 229920000298 Cellophane Polymers 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 239000004100 Oxytetracycline Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 229960005475 antiinfective agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229960000625 oxytetracycline Drugs 0.000 description 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 2
- 235000019366 oxytetracycline Nutrition 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- AARNXMRADQFOEB-FDIQSBBYSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-1-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC(O)[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 AARNXMRADQFOEB-FDIQSBBYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- QSAVEGSLJISCDF-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 1
- 150000005011 4-aminoquinolines Chemical class 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- TWDJIKFUVRYBJF-UHFFFAOYSA-N Cyanthoate Chemical compound CCOP(=O)(OCC)SCC(=O)NC(C)(C)C#N TWDJIKFUVRYBJF-UHFFFAOYSA-N 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 1
- UDKABVSQKJNZBH-DWNQPYOZSA-N Melengestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UDKABVSQKJNZBH-DWNQPYOZSA-N 0.000 description 1
- GZHFODJQISUKAY-UHFFFAOYSA-N Methantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 GZHFODJQISUKAY-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- TUQLBJAHRWROHB-UHFFFAOYSA-N acetic acid;1-(1h-indol-3-yl)butan-2-amine Chemical compound CC(O)=O.C1=CC=C2C(CC(N)CC)=CNC2=C1 TUQLBJAHRWROHB-UHFFFAOYSA-N 0.000 description 1
- NMZSAMXFINECBQ-UHFFFAOYSA-N acetic acid;1-(1h-indol-3-yl)propan-2-amine Chemical compound CC([O-])=O.C1=CC=C2C(CC([NH3+])C)=CNC2=C1 NMZSAMXFINECBQ-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003619 algicide Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940058934 aminoquinoline antimalarials Drugs 0.000 description 1
- 150000005010 aminoquinolines Chemical class 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940055075 anticholinesterase parasympathomimetics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000012431 aqueous reaction media Substances 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- OPNPQXLQERQBBV-UHFFFAOYSA-N carbromal Chemical compound CCC(Br)(CC)C(=O)NC(N)=O OPNPQXLQERQBBV-UHFFFAOYSA-N 0.000 description 1
- 229960001658 carbromal Drugs 0.000 description 1
- 229950009852 carfenazine Drugs 0.000 description 1
- TVPJGGZLZLUPOB-SPIKMXEPSA-N carphenazine maleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C12=CC(C(=O)CC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 TVPJGGZLZLUPOB-SPIKMXEPSA-N 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003996 chlormadinone Drugs 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-O codeine(1+) Chemical compound C([C@H]1[C@H]([NH+](CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-O 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- QUQFTIVBFKLPCL-UHFFFAOYSA-L copper;2-amino-3-[(2-amino-2-carboxylatoethyl)disulfanyl]propanoate Chemical compound [Cu+2].[O-]C(=O)C(N)CSSCC(N)C([O-])=O QUQFTIVBFKLPCL-UHFFFAOYSA-L 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
- 229960001815 cyclopentolate Drugs 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- YHKBUDZECQDYBR-UHFFFAOYSA-L demecarium bromide Chemical compound [Br-].[Br-].C=1C=CC([N+](C)(C)C)=CC=1OC(=O)N(C)CCCCCCCCCCN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 YHKBUDZECQDYBR-UHFFFAOYSA-L 0.000 description 1
- 229960003715 demecarium bromide Drugs 0.000 description 1
- 239000003975 dentin desensitizing agent Substances 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- OVXQHPWHMXOFRD-UHFFFAOYSA-M ecothiopate iodide Chemical compound [I-].CCOP(=O)(OCC)SCC[N+](C)(C)C OVXQHPWHMXOFRD-UHFFFAOYSA-M 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 1
- 229960000445 ethisterone Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229950002420 eucatropine Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- RGUQWGXAYZNLMI-UHFFFAOYSA-N flumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 1
- 229960003028 flumethiazide Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 229960000857 homatropine Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229950005360 hydroxyamfetamine Drugs 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960001011 medrysone Drugs 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004805 melengestrol Drugs 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960001470 methantheline Drugs 0.000 description 1
- 229960001869 methapyrilene Drugs 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 1
- 229960001383 methylscopolamine Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 229960001858 norethynodrel Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 239000002297 parasiticide Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940100008 phospholine iodide Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000009342 ragweed pollen Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000025508 response to water Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 239000003128 rodenticide Substances 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960003141 secobarbital sodium Drugs 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- AXXJTNXVUHVOJW-UHFFFAOYSA-M sodium;5-pentan-2-yl-5-prop-2-enylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC=C)C(=O)NC(=O)[N-]C1=O AXXJTNXVUHVOJW-UHFFFAOYSA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960002135 sulfadimidine Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960002597 sulfamerazine Drugs 0.000 description 1
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- AIUHRQHVWSUTGJ-UHFFFAOYSA-N thiopropazate Chemical compound C1CN(CCOC(=O)C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 AIUHRQHVWSUTGJ-UHFFFAOYSA-N 0.000 description 1
- 229960004728 thiopropazate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 229960002485 trolnitrate Drugs 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
Definitions
- An osmotic active agent dispenser is comprised of l) a first compartment of relatively impervious material containing an active agent and provided with an aperture for releasing said active agent to the exterior of the dispenser; (2) a second compartment of controlled permeability to water containing a solution of an osmotically effective solute which exhibits an osmotic pressure gradient against water; and (3) a movable barrier member separating the first from the second compartment.
- the barrier member is slidably respon sive to an increase in volume in the second compartment via absorption of water therein; whereby as water flows by osmosis into the compartment (2) of the dispenser in a tendency towards osmotic equilibrium with its environment, corresponding pressure is exerted behind the barrier (3) driving it into and diminishing the volume of the compartment (1), in turn continuously ejecting active agent thereout at an osmotically controlled rate over a prolonged period of time.
- the dispenser is comprised of a plurality of capsule half shells one of which compartmentalizing and being free to move within the device, thereby defining a closure for both the active agent compartment and the solution compartment.
- This invention relates to an osmotic dispenser, and, more especially, to an osmotic dispenser, simple in construction, capable of releasing to its outside environment concentrations of active agent at an osmotically controlled rate over a prolonged period of time.
- active agent denotes any drug (as defined, infra); composition in any way affecting any biological entity; substance having a nutrient or stimulating action, or growth inhibiting, destroying or any regulating action on plant growth, controlled or otherwise; substance to be assimilated by any organism, e.g., human being, animal, or lower order organism, for its nourishment or for regulating its growth;
- suitable active agents for use with the dispenser of this invention include, without limitation, those which are generally capable of:
- Controlling or protecting an environment or living body by attracting, disabling, inhibiting, killing, modifying, repelling or retarding an animal or microorganism, such as food and non-food baits, attractants and lures, biocides, pesticides, algicides, parasiticides, rodenticides, insecticides, fungicides, and the like;
- Controlling or affecting generically an environment as by introducing a catalyst or metering a reactant into a reacting chemical system, or by effecting any chemical process therein, such as a fermentation, including propagation and/or attenuation of a microorganism.
- environment surroundings
- habitat as used hereinabove and herein denote any prospective situs for the osmotic dispenser of this invention which is comprised of or will provide sufficient water for absorption into the device to develop the needed osmotic pressure on which its motive force depends; and implicit in the foregoing definition of active agent" one that will develop its action in the presence of such environment, surroundings or habitat, or one that will develop its action on a remote and/or another environment, which need not be aqueous. as hereinafter described and illustrated.
- compositions, products, appliances, depositors, applicators, dispensers, injectors and devices are well known in the art in which the timing or spacing of administration or absorption of an active agent is regulated by the structure or physical arrangement of elements so that a single administration provides a gradual but continuous or sustained feeding of the active agent to a system by slow or differential release. All of such prior art devices and the like, however, are characterized by at least one feature which adversely affects control over their rate of sustained or differential release or which detracts from the practical benefits attendant the long-term continuous administration of various active agents both to humans, animals, and into other environments.
- the Rose et al. injector consists of three compartments and a clamp to hold a semi-permeable membrane.
- the motive force of the injector depends on the osmotic pressure developed by a saturated aqueous solution of Congo red against water.
- This solution is contained in a partially collapsed rubber compartment and is separated from a second water compartment by the semi-permeable cellophane membrane.
- the partially collapsed bag is placed in a glass ampoule, with the drug compartment of the device being defined by the space between the Congo red bag and the glass ampoule.
- the ampoule is also provided with drugrelease means and when the drug compartment is charged with a drug solution by osmosis water will move into the Congo red solution thus expanding the rubber compartment and providing the mechanical force to eject the drug out of the apparatus.
- the Rose et al. device has substantial inherent disadvantages which has prevented its wide acceptance by the medical community.
- the use of a solution as the drug vehicle l will not permit high concentration of drug to be embodied within the device; (2) such solutions exhibit the deleterious tendency to be released from the device by simple leaching; and (3) many chemical substances on prolonged storage in a dissolved state undergo chemical deterioration.
- the reference injector is moreover cumbersome in that it depends for its motive force on a separate water compartment rather than its environment.
- Another object of this invention is to provide an improved osmotic dispenser which overcomes problems inherent in related devices heretofore proposed.
- Another object of this invention is to provide an improved osmotic dispenser which will permit high concentrations of active agent to be embodied therein, and which high concentrations of active agent will not exhibit the tendency to be leached from the device nor be decreased in potency by chemical breakdown.
- Another object of this invention is to provide an osmotic active agent dispenser which depends for its motive force on its environment.
- Still another object of this invention is to provide an osmotic dispenser, the osmotic membrane of which can be fabricated from many and varied suitable materials, and which is capable of using a variety of solutions of osmotically effective solutes to produce the osmotic driving force.
- Yet another object of this invention is to provide an osmotic dispenser of simple design which will release active agent solution, or gel, or semisolid active agent formulation, at a controlled rate over a prolonged period of time.
- an osmotic dispenser comprised of a first compartment of relatively impervious material containing an active agent and a second compartment containing a solution of an osmotically effective solute which exhibits an osmotic pressure gradient against water. Separating the said first from the said second compartment, and defining a wall member common to each of said compartments, is a sliding or movable barrier of impervious material.
- the enclosure, whether of integral construction or not, defining the remainder of the second compartment, wherein the osmotic motive force of the dispenser is developed, is at least in part comprised of membrane which exhibits controlled permeability to water.
- a further feature of this invention resides in an osmotic active agent dispenser comprised of a plurality of capsule half shells, similar in shape to pharmaceutical hard gelatin half shells, with a first and a second half shell being securedly affixed in capsular configuration, and a third half shell frictionally disposed in such capsule but free to slidably move therein.
- the said capsule is thereby divided into the two compartments with the third half shell defining the wall member common to each of same.
- a fourth half shell defines capping means for the dispensing head of the capsule.
- FIG. 1 is a cross-sectional view of an osmotic dispenser of this invention
- FIG. la is a fragmentary cross-sectional view of a modification in the dispensing head of the osmotic dispenser of FIG. 1;
- FIG. 1b is a fragmentary cross-sectional view of another modification in the dispensing head of the osmotic dispenser of FIG. 1;
- FIG. 2 is a cross-sectional view of another osmotic dispenser of this invention.
- FIG. 3 is a cross-sectional view of yet another osmotic dispenser of this invention.
- FIG. 4 is a cross-sectional view of still another osmotic dispenser of this invention.
- FIG. 5 is an exploded view of the dispenser of FIG. 4.
- an osmotic dispenser 10 is comprised of a rigid, impervious housing member or plastic shell 12, capsule-shaped and having a thickened rounded end and bored with one or more capillary ducts or openings 14 approximately 0.5 mm in diameter.
- the open end of the plastic shell 12 is sealed or closed off with a membrane 16 which exhibits controlled permeability to water, advantageously a semipermeable, anisotropic cellulose acetate membrane of the type used in reverse osmosis water desalination.
- the membrane 16 is backed up by and supported by a stiff water-porous disc 18 which is advantageously cemented in place in the said shell 12 and is fabricated from such materials as, for example,.a ceramic frit.
- a sliding barrier plug, disc or seal 20, of impermeable barrier material compartmentalizes the shell 12 into an active agent compartment 22 and a compartment 24 wherein the motive force of the dispenser is developed.
- the said first compartment 22 contains the active agent, advantageously a drug, in a gel, paste or other semisolid state (albeit a solution or concentrated solution of active agent will sometimes suffice), and the active agent, if a drug, is preferably normally carried in an oil phase, such as cocoa butter.
- the said compartment 24 contains a solution of an osmotically effective solute which exhibits an osmotic pressure gradient against water; and the sliding barrier plug 20 is so constructed as to movably provide and maintain a tight barrier between the active agent phase in the first compartment and the osmotic fluid in the second. Without this tight barrier undesirable contamination could take place.
- the capillary ducts or active agent release means 14 provide communication from the interior of the compartment 22 to the exterior of the device 10, in this instance the said means being comprised of one or more of said capillary ducts 14 drilled in the thickened rounded end or dispensing head of the said shell 12.
- the plug 20 is frictionally disposed but is free to move within the device by sliding while at the same time maintaining an impenetrable or contamination preventing barrier between the active agent phase and the osmotic fluid.
- the device when the active agent is a drug or other agent for treating, etc., a living organism, is either physically inserted or surgically implanted in the body of the organism, typically a mammal, or is administered via the gastrointestinal tract.
- the body of the organism typically a mammal
- water will be absorbed therein from either body tissues or body fluids through the stiff porous support 18 and through the water permeable membrane 16 in an effort to reach osmotic equilibrium, i.e., a transition from hypertonicity to isotonicity.
- osmotic equilibrium i.e., a transition from hypertonicity to isotonicity.
- Such pressure serves to drive the said barrier plug forward at a constant rate thus forcing the drug through the capillaries 14 at an osmotically controlled and constant rate into the external environment.
- the use of any semisolid drug vehicle will reduce the tendency to release the drug, or any other active agent for that matter, by leaching and will permit high concentrations thereof to be embodied within the device.
- the dispenser is of insufficient specific gravity to maintain placement at the desired location.
- the weight should be sufficient to provide a specific gravity of at least 1.5.
- a weight or ballast can be placed in the device, such as the steel ball 26 of FIG. 1.
- suitable weights comprise iron plugs, iron ore tablets, brass plugs, ceramic plugs, or the like.
- the device When the active agent is other than a drug or similar agent, or is intended for use other than in a living organism, the device is introduced into the desired aqueous environment to produce the desired effect exactly as would be any of the known means for accomplishing a like result. And this is generally a mere physical insertion, such as by placing a pesticide containing device in a river or stream, or a catalyst containing device in an aqueous reaction medium.
- long flexible tubing of polythene or the like can be extended from the dispensing head of the device of FIG. 1. See FIG. la.
- the device can be deposited at a site remote from the desired point of application and still release its active agent contents through the dispensing head and then through the tube directly to said point.
- This permits placement of the dispenser in an aqueous environment and release of the active agent into another environment which need not be aqueous.
- the dispensing head can also be provided with a check valve, for example, a one way ball valve (see FIG. 1b), to prevent back flow of active agent or other materials from the external environment into the device.
- FIG. 1 device The design of the FIG. 1 device is moreover unique in that it requires a membrane of but limited surface area. This because of the ready availability of the highly water-permeable cellulose acetate membranes designed for use in reverse osmosis processes for water desalination. These membranes, typically and preferably anisotropic membranes, are highly permeable to water (allow relatively rapid rates of water transmission) but are relatively impermeable to salt, thus permitting their use in relatively small exposure area devices.
- FIG. 2 there is depicted an osmotic active agent dispenser 10 which allows for higher available exposure area of the membrane 16 and, accordingly, which design takes advantage of the availability of a far greater number of membranes than the semi-permeable, anisotropic cellulose acetate membranes of the type used in reverse osmosis water desalination.
- both the membrane 16 and the stiff water porous support 18 are cup shaped rather than a flat disc, with the former being adhered or cemented to the latter.
- porous disc or cup 18/membrane l6 assembly can alternatively merely be snapped or press-fit into the porous shell 12 and be there secured without the need for added adhesive or cement, and in such manner this mechanical lock in and of itself prevents any leakage.
- a separator of porous paper, fabric or the like can conveniently be disposed between the support 18 and membrane 16. This prevents the membrane from being punctured or drawn into too tight a contact with the casing, thereby assuring that the entire membrane is exposed to the aqueous environment.
- the separator 20 may take the configuration of a capsule half shell, rather than a plug or disc (as in, for example, the design of FIG. 3).
- FIG. 3 illustrates another embodiment of this invention wherein an osmotic active agent dispenser 30, similar to that of FIG. 1, is comprised of three, and optionally four capsule half shells, similar in shape to pharmaceutical hard gelatin half shells.
- the shell 32 is optional and designed to rapidly dissolve in the aqueous environment in which the device is intended to be placed, for example, is designed to rapidly dissolve in body fluids (when the active agent is a drug or other agent for treating, etc., a living organism).
- Shell 32 thus provides a capping means for the release port 44 of the capsule.
- the shells 34 and 36 are rigid and resistant to dissolution and degradation in the aqueous environment or body fluids, but exhibit controlled permeability to moisture.
- the shells 34 and 38 are cemented tightly on manufacture, in capsular configuration, with shell 36 being free to move or slide in response to water flowing into the compartment 40, which compartment contains the solution of the osmotically effective solute exhibiting an osmotic pressure gradient against water, and said compartment 40 being defined by the walls of the said shells 36 and 38 and to some extent by the walls of the said shell 34.
- the active agent advantageously a drug, is contained in the compartment 42 which is defined by the space between the walls of the shells 34 and 36.
- Shell 34 is provided with an aperture or orifice 4-4 from which the active agent or drug exits upon expansion of the solution compartment 40 which forces the shell 36 further into the active agent compartment 42, thus diminishing the active volume of the latter.
- the shell 36 is frictionally set into the shells 34 and 38 to such an extent (1) that it is free to move in response to absorption of water through the permeable shell 38 and concomitant increase in volume of the said compartment 40 but (2) the fit is tight enough as to prevent commingling and contamination of the contents of the several compartments 40 and 42 by leakage.
- the shell 38 most preferably is a composite comprised of a rigid, highly porous half shell 46 lined with membrane 48 which is controlledly permeable to water. Such composite is readily fabricated by either lining or laminating the membrane 48 to the porous half shell 46, or by casting a film of the said membrane 48 onto and preferably within the said shell 46.
- the aforementioned casting about the porous shell is advantageously perfected by depositing the film from a solution of membrane forming material in a solvent, e.g., a 20 percent solution of cellulose acetate in an acetone-ethanolethyl lactate mixed solvent, 65 percent 20 percent 15 percent. In casting the film, care should be taken that the pores of the shell 46 do not become clogged.
- FIG. 1, FIG. 2 or FIG. 3 type is admirably suited for the continuous administration of the antibiotic oxytetracycline to beef cattle from the rumen.
- This because such devices can easily be fabricated of a size, weight and shape as to be retained in the rumen of polygastric animals to release drug or similar agent thereto at a carefully controlled rate.
- Other variations on the basic theme would be readily apparent to the skilled artisan. Although particular configurations may be designed for specific body uses, each of these configurations is applicable to use in other environments.
- the membrane 16 of FIGS. 1 and 2 and the half shell lining 48 of FIG. 3 can be formed from a wide variety of materials permeable or semi-permeable to solvent (water) but not to solute, i.e., those suitable for the construction of an osmotic cell.
- the membrane should be substantially impermeable to passage of the osmotically effective solute so as to prevent loss thereof.
- Typical membranes are isotropic membranes such as unplasticized cellulose acetate, plasticized cellulose acetate, reinforced cellulose acetate, cellulose diand triacetate, ethyl cellulose; anisotropic reverse osmosis membranes which typically are made of cellulose acetate; silicone rubbers, polyurethanes, natural rubber, and hydrolyzed ethylene/vinyl acetate copolymers.
- Isotropic membranes have less water permeability than do the anisotropic membranes. Also, with both types of membranes, increasing the acetate content of the cellulose acetate polymer decreases the water permeability. Since, as previously described, the surface area of the membrane is relatively limited in a device of FIG.
- a cellulose acetate membrane suitable for this limited surface area application is Eastman Chemical Products Type R 97, which is rated to be permeable to 1.5 to 2 cc/cm /day at atmospheric pressure, against a saturated solution of K 80 at 39 C.
- a specific example of the design of FIG. 1 constructed with polymethylmethacrylate dispensing head, separator and tubing having an inner diameter of 1.9 cm, is capable of delivering 4 to 6 cc of active agent, advantageously a drug, per day.
- the membrane used was an isotropic cellulose acetate membrane, with no plasticizer, having an acetate substitution of 2.4, being 3 mils thick, and passing water at the rate of mg/cm per day against a saturated magnesium sulfate solution at 39 C.
- the membranes too are insoluble, and chemically compatible with the salt solution and any excess solute therein.
- the membranes are also biologically inert, non-irritating to body tissues and non-allergenic.
- membranes of controlled high water permeability are indicated; membranes of lower water permeability are used to provide slower and more prolonged delivery.
- the impermeable plastic shell 12 of FIGS. 1 and 2 and the half shell 34 of FIG. 3 too are insoluble and can be formed of polystyrene, polyethylene, polypropylene, polyvinyl chloride, reinforced epoxy resin, polymethylmethacrylate, etc., sheet metal (e.g., aluminum, cop per, steel, etc.), galvanized pipe, or styrene/acrylonitrile copolymer. It is of course intended that such casing or shell act as a barrier to the transport of water. Again, for drug depot applications the same are advantageously biologically inert, non-irritating to body tissues and non-allergenic.
- the barrier plug 20 and the half shell 36 can be formed of materials identical to those used for fabricating the shells 12 and 34.
- Espe cially preferred of the above are the impermeable or refractory plastics.
- the materials would be highly porous since it is not intended that the member 18 and the half shell 46 in any way act as a barrier to or restrict the transport of water.
- l-Ialf shell 32 of the FIG. 3 dispenser can be formed from any material which will rapidly dissolve in the aqueous environment in which the device is intended to be placed, such as gelatin and such material again being biologically inert, non-irritating to body tissues and non-allergenic when the device is designed for placement in the body.
- each shell and half shell has a wall thickness of 0.5 to 50 mils, preferably of 5 to 50 mils, and the water permeable membranes have a wall thickness of 1 to 10 mils.
- FIG. 4 and 5 One specific embodiment of a dispenser fabricated in accordance with the invention, and as illustrated in FIG. 4 and 5, fitted witha 3 mils thick semi-permeable membrane 16, and having the following dimensions and specifications:
- Active agent Approximately 60 percent tetracycline hydrochloride dispersed in 40 percent cocoa butter medium;
- Osmotic solution Saturated aqueous solution of K 80 containing sufficient excess solute in solid form to maintain solution saturated over a period of at least 3 days;
- Water permeable membrane Cellulose diacetate, with a degree of acetyl substitution of 2.4;
- Shell 12 Soft polyethylene; Threaded end cap 50: Soft polyethylene; Delivery cap 52: Soft polyethylene; Barrier member 20: Soft polyethylene; Chamfered ring 54: Polycarbonate; Membrane support 18: Polystyrene; Diameter of delivery port 14: 0.0625 inch; Diameter of orifices in cap 50: 0.0625 inch; Diameter of orifices in support 18: 0.1250 inch; is capable of delivering gm of the active drug per day, over a period of 3 days, when administered to the rumen of a 500 pound calf, whereat it is retained, via the gastrointestinal tract. It will be appreciated that the design of the FIG. 4 and FIG. 5 device is quite similar to that of FIG.
- the cap 50 houses the membrane 16 and the membrane support 18.
- a separator of porous paper, fabric or the like can be placed between either or both of the membrane support 18 and end cap 50 and the semipermeable membrane 16. Same, as heretofore mentioned, prevents the membrane from being punctured or drawn into too tight a contact with its housing, thereby additionally assuring that the entire membrane is exposed to the aqueous environment.
- any of the drugs used to treat the body can be compartmentalized as the active agent in any of the osmotic dispensers of this invention.
- Drug is used herein in its broadest sense as including any composition of substance that will produce a pharmacological or biological response.
- Suitable drugs for use in therapy with the dispenser of the invention include without limitation:
- Protein drugs such as insulin
- Desensitizing agents such as ragweed pollen antigens, hay fever pollen antigens, dust antigen and milk antigen;
- Vaccines such as small pox, yellow fever, distemper, hog cholera, fowl pox, antivenom, scarlet fever, diphtheria toxoid, tetanus toxoid, pigeon pox, whooping cough, influenza, rabies, mumps, measles, poliomyelitis, Newcastle disease, etc.;
- Anti-infectives such as antibiotics, including penicillin, tetracycline, chlortetracycline, bacitracin, nystatin, streptomycin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethizole, sulfamethazine, sulfadiazine, sulfamerazine, and sulfisoxazole; anti-virals including idoxuridine; and other anti-infectives including nitrofurazone and sodium propionate;
- antibiotics including penicillin, tetracycline, chlortetracycline, bacitracin, nystatin, streptomycin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin
- Anti-allergenics such as antazoline, methapyrilene,
- Anti-inflammatories such as hydrocortisone; cortisone, hydrocortisone acetate, dexamethasone, dexamethasone 2 l-phosphate, fluocinolone, triamcinolone, medrysone, prednisolone, prednisolone 21-phosphate, and prednisolone acetate;
- Decongestants such as phenylephrine, naphazoline, and tetrahydrozoline;
- Miotics and anticholinesterases such as pilocarpine, eserine salicylate, carbachol, di-isopropyl fluorophosphate, phospholine iodide, and demecarium bromide;
- Mydriatics such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, and hydroxy-amphetamine;
- Sedatives and Hypnotics such as pentobarbital sodium, phenobarbital, secobarbital sodium, codeine, (a-bromoisovaleryl) urea, carbromal;
- Psychic Energizers such as 3-( 2-aminopropyl) indole acetate and 3-(2-aminobutyl) indole acetate;
- Tranquilizers such as reserpine, chlorpromazine,
- Estrogens such as estrone, 17 B -estradiol, ethinyl estradiol, and diethyl stilbesterol;
- Progestational agents such as progesterone, megestrol, melengestrol, chlormadinone, ethisterone, norethynodrel, l9-nor-progesterone, norethindrone, medroxyprogesterone and l 7 a-hydroxy-progesterone;
- Humoral agents such as the prostaglandins, for example
- PGE P05 and PGF 18 Antipyretics such as aspirin, sodium salicylate,
- Antispasmodics such as atropine, methantheline,
- Anti-malarials such as the 4-aminoquinolines, 8-
- Antihistamines such as diphenhydramine, dimenhydrinate, tripelennamine, perphenazine, and carphenazine;
- Cardioactive agents such as hydrochlorothiazide,
- Nutritional agents such as vitamins, essential amino acids and essential fats
- Anti-Parkinsonism agents such as L-dopa, (L-
- osmotic dispensers having the same or different physiological activity as those recited above can be employed in osmotic dispensers within the scope of the present invention; Suitable mixtures of drugs can, of course, be dispensed with equal facility as with single component systems.
- Drugs can be in various forms, such as uncharged molecules, components of molecular complexes, or non-irritating pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulphate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc.
- pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulphate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc.
- salts of metals, amines, or organic cations e.g., quaternary ammonium
- simple derivatives of the drugs such as ethers, esters, amides, etc.
- body pH, enzymes, etc. can be employed.
- the amount of drug incorporated in the osmotic dispenser varies widely depending on the particular drug, the desired therapeutic effect, and the time span for which it takes the drug to be released. Since a variety of dispensers in a variety of sizes and shapes are intended to provide complete dosage regimes for therapy for a variety of maladies, there is no critical upper limit on the amount of drug incorporated in the dispenser. The lower limit too will depend on the activity of the drug and the time span of its release from the dispenser. Thus it is not practical to define a range for the therapeutically effective amount of drug to be released by the dispenser.
- the motive force of the dispenser of this invention depends on the osmotic pressure generated by the solution of the osmotically effective solute contained in the compartments 24 and 40, which solution exhibits an osmotic pressure gradient against water.
- Said solution is most preferably a saturated aqueous salt solution.
- the compartment containing the solution also contains excess solute in solid form.
- Various osmotically effective solutes can be used.
- the excess solid solute can be in the form of dispersed particles or preferably in the form of a pellet.
- the solution can initially be a solution of the same or of a osmotically effective solute difi'erent than the solid excess solute.
- the osmotic dispenser can be fabricated in any con-- venient shape for either physical insertion or implantation in the body, or for administration via the gastrointestinal tract, or for introduction into any desired aqueous environment. Dimensions of the device can thus vary widely and are not of controlling importance.
- the lower limit of the size of the device is governed by the amount of the particular active agent to be supplied to the aqueous environment to elicit the desired response, as well as by the form the dosage unit takes, for example, in cases of specific body uses, implantate, bolus, IUD, IVD, vaginal ring, uterine capsule for fertility suppression, artificial gland, pessary, prosthesis, suppository, and the like.
- implantate, bolus, IUD, IVD, vaginal ring, uterine capsule for fertility suppression, artificial gland, pessary, prosthesis, suppository, and the like Likewise with respect to the upper limit on the size of the device.
- the dispenser can be of such size as to deliver 1 to 2 0c of drug formulation per day and to deliver a total of 5 to 10 cc of drug formulation over a 5 to 10 day period.
- the pump can deliver drug more slowly up to and in excess of 1 year. It is preferred that the construction of the several compartments and of the active agent release means be such that the osmotic driving pressure developed is at least 10 times greater than the back pressure generated by the active agent formulation.
- the invention provides, in an osmotic dispenser, a reliable means for releasing effective concentrations of active agent contained therein to the body of a living organism, or to any other aqueous environment, at an osmotically controlled rate and over a prolonged period of time.
- prime advantages of the dispenser of the invention are thatit is simple in construction and exhibits all of the practical advantages of the long-term continuous administration of various active agents both to humans, animals, and into other environments, and that the active agent contained therein will not exhibit the tendency to be leached therefrom.
- An osmotic active agent dispenser comprised of a plurality of capsule half shells, with a first and a second half shell securedly afiixed in capsular configuration, and a third half shell frictionally disposed in such capsule but free to slidably move therein, the said capsule being thereby divided into two compartments, an active agent compartment containing active agent and provided with release means therefor to the exterior of the dispenser and a second compartment containing a solution of an osmotically effective solute which exhibits an osmotic pressure gradient against water;
- the shell of the capsule comprising the solution compartment is rigid, resistant and water pervious;
- the shell of the capsule comprising the active agent compartment is rigid, resistant and water impervious;
- the interior half shell is rigid, resistant and water impervious, the open end of which is in communicating relationship with the said second compartment; whereby as water flows by osmosis into the solution compartment in a tendency towards osmotic equilibrium with its environment the said solution compartment expands by forcing the interior shell further into
- osmotic dispenser as defined by claim 1, wherein the osmotically effective solute is selected from the group consisting of magnesium sulphate, magnesium chloride, sodium chloride, potassium sulphate, sodium carbonate, sodium sulphite, sodium sulphate, sodium bicarbonate, potassium acid phthalate, calcium bicarbonate, potassium acid phosphate, raffin0se,'tartan'c acid, succinic acid, calcium succinate, calcium lactate and magnesium succinate.
- the osmotically effective solute is selected from the group consisting of magnesium sulphate, magnesium chloride, sodium chloride, potassium sulphate, sodium carbonate, sodium sulphite, sodium sulphate, sodium bicarbonate, potassium acid phthalate, calcium bicarbonate, potassium acid phosphate, raffin0se,'tartan'c acid, succinic acid, calcium succinate, calcium lactate and magnesium succinate.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
An osmotic active agent dispenser is comprised of (1) a first compartment of relatively impervious material containing an active agent and provided with an aperture for releasing said active agent to the exterior of the dispenser; (2) a second compartment of controlled permeability to water containing a solution of an osmotically effective solute which exhibits an osmotic pressure gradient against water; and (3) a movable barrier member separating the first from the second compartment. The barrier member is slidably responsive to an increase in volume in the second compartment via absorption of water therein; whereby as water flows by osmosis into the compartment (2) of the dispenser in a tendency towards osmotic equilibrium with its environment, corresponding pressure is exerted behind the barrier (3) driving it into and diminishing the volume of the compartment (1), in turn continuously ejecting active agent thereout at an osmotically controlled rate over a prolonged period of time. In a specific embodiment, the dispenser is comprised of a plurality of capsule half shells one of which compartmentalizing and being free to move within the device, thereby defining a closure for both the active agent compartment and the solution compartment.
Description
Elite tates atf: r 91 iguchi et all.
[ May 15, R973 OSMOTIC DISPENSER [75] Inventors: Takeru Higuchi; Harold M. Leeper,
both of Lawrence, Kans.
[73] Assignee: Alza Corporation, Palo Alto, Calif.
[22] Filed: Jan. 13, 1971 [2]] Appl. No.: 106,130
[52] U.S. Cl. ..l28/260, 128/272, 128/213 [51] Int. Cl. ..A61m 7/00, A6lm 31/00 [58] Field of Search. ..l28/l27l3l,
Primary Examiner-Richard A. Gaudet Assistant Examiner.l. C. McGowan A ttorney-Steven D. Goldby and Paul L. Sabatine [57] ABSTRACT An osmotic active agent dispenser is comprised of l) a first compartment of relatively impervious material containing an active agent and provided with an aperture for releasing said active agent to the exterior of the dispenser; (2) a second compartment of controlled permeability to water containing a solution of an osmotically effective solute which exhibits an osmotic pressure gradient against water; and (3) a movable barrier member separating the first from the second compartment. The barrier member is slidably respon sive to an increase in volume in the second compartment via absorption of water therein; whereby as water flows by osmosis into the compartment (2) of the dispenser in a tendency towards osmotic equilibrium with its environment, corresponding pressure is exerted behind the barrier (3) driving it into and diminishing the volume of the compartment (1), in turn continuously ejecting active agent thereout at an osmotically controlled rate over a prolonged period of time. In a specific embodiment, the dispenser is comprised of a plurality of capsule half shells one of which compartmentalizing and being free to move within the device, thereby defining a closure for both the active agent compartment and the solution compartment.
9 Claims, 7 Drawing Figures 'PATENTEDHAY 1 51915 SHEET 1 OF 2 murrrnii INV ENTORS TAKERU HIGUCHI HAROLD M. LEEPER ATTOR Y mvzmons ATTO sum 2 or 2 PATENIEDMAH 5 ms FIG. 4
TAKERU H|GUCHI HAROLD M. LEEPER ()SMOTIC DISPENSER Takeru I-Iiguchi copending application, Ser. No. 106,131 filed Jan. 13, 1971, assigned to the assignee of the present invention.
FIELD OF THE INVENTION This invention relates to an osmotic dispenser, and, more especially, to an osmotic dispenser, simple in construction, capable of releasing to its outside environment concentrations of active agent at an osmotically controlled rate over a prolonged period of time.
DEFINITION OF TERMS The expression active agent as used herein denotes any drug (as defined, infra); composition in any way affecting any biological entity; substance having a nutrient or stimulating action, or growth inhibiting, destroying or any regulating action on plant growth, controlled or otherwise; substance to be assimilated by any organism, e.g., human being, animal, or lower order organism, for its nourishment or for regulating its growth;
' substance exhibiting any of the above activities to be directly applied to the habitat, surroundings or environment of any of the above organisms; and substance having any other effect on any other environment, especially any aqueous environment.
Therefore, suitable active agents for use with the dispenser of this invention include, without limitation, those which are generally capable of:
1. Preventing, alleviating, treating or curing abnormal and pathological conditions of the living body of such means as destroying a parasitic organism or limiting the effect of the disease or abnormality by chemically altering the physiology of the host or parasite;
2. Maintaining, increasing, decreasing, limiting or destroying a physiologic body or plant function, e.g., vitamin compositions, sex sterilants, fertility inhibitors, fertility promoters, growth promoters, and the like;
3. Diagnosing a physiological condition or state;
4. Controlling or protecting an environment or living body by attracting, disabling, inhibiting, killing, modifying, repelling or retarding an animal or microorganism, such as food and non-food baits, attractants and lures, biocides, pesticides, algicides, parasiticides, rodenticides, insecticides, fungicides, and the like;
5. Preserving, disinfecting or sterilizing; and
6. Controlling or affecting generically an environment, as by introducing a catalyst or metering a reactant into a reacting chemical system, or by effecting any chemical process therein, such as a fermentation, including propagation and/or attenuation of a microorganism.
The terms environment," surroundings" and habitat as used hereinabove and herein denote any prospective situs for the osmotic dispenser of this invention which is comprised of or will provide sufficient water for absorption into the device to develop the needed osmotic pressure on which its motive force depends; and implicit in the foregoing definition of active agent" one that will develop its action in the presence of such environment, surroundings or habitat, or one that will develop its action on a remote and/or another environment, which need not be aqueous. as hereinafter described and illustrated.
BACKGROUND OF THE INVENTION Many and varied compositions, products, appliances, depositors, applicators, dispensers, injectors and devices are well known in the art in which the timing or spacing of administration or absorption of an active agent is regulated by the structure or physical arrangement of elements so that a single administration provides a gradual but continuous or sustained feeding of the active agent to a system by slow or differential release. All of such prior art devices and the like, however, are characterized by at least one feature which adversely affects control over their rate of sustained or differential release or which detracts from the practical benefits attendant the long-term continuous administration of various active agents both to humans, animals, and into other environments.
An osmotic dispenser too has been proposed which is capable of delivering drug solution at a relatively constant rate. See Rose and Nelson, Austral. J. Exp. BioL, 33 pp. 415 420 (1955). The Rose et al. injector consists of three compartments and a clamp to hold a semi-permeable membrane. The motive force of the injector depends on the osmotic pressure developed by a saturated aqueous solution of Congo red against water. This solution is contained in a partially collapsed rubber compartment and is separated from a second water compartment by the semi-permeable cellophane membrane. The partially collapsed bag is placed in a glass ampoule, with the drug compartment of the device being defined by the space between the Congo red bag and the glass ampoule. The ampoule is also provided with drugrelease means and when the drug compartment is charged with a drug solution by osmosis water will move into the Congo red solution thus expanding the rubber compartment and providing the mechanical force to eject the drug out of the apparatus.
The Rose et al. device, however, has substantial inherent disadvantages which has prevented its wide acceptance by the medical community. In the first place, the use of a solution as the drug vehicle l will not permit high concentration of drug to be embodied within the device; (2) such solutions exhibit the deleterious tendency to be released from the device by simple leaching; and (3) many chemical substances on prolonged storage in a dissolved state undergo chemical deterioration. The reference injector is moreover cumbersome in that it depends for its motive force on a separate water compartment rather than its environment. In addition, the Rose et al. device is essentially only a research or experimentation tool, is complex in construction and is at least literally restricted to a Congo red solution to produce the osmotic driving force and to a cellophane osmotic membrane. See also Rose and Nelson, Austral. J. Exp. BioL, 33 pp. 41 l 414 (1955).
SUMMARY OF THE INVENTION Accordingly, it is a primary object of this invention to provide an osmotic dispenser, simple in construction, which exhibits all of the practical benefits of longterrn continuous administration of various active agents both to animals, humans, and into other environments.
Another object of this invention is to provide an improved osmotic dispenser which overcomes problems inherent in related devices heretofore proposed.
Another object of this invention is to provide an improved osmotic dispenser which will permit high concentrations of active agent to be embodied therein, and which high concentrations of active agent will not exhibit the tendency to be leached from the device nor be decreased in potency by chemical breakdown.
Another object of this invention is to provide an osmotic active agent dispenser which depends for its motive force on its environment.
Still another object of this invention is to provide an osmotic dispenser, the osmotic membrane of which can be fabricated from many and varied suitable materials, and which is capable of using a variety of solutions of osmotically effective solutes to produce the osmotic driving force.
Yet another object of this invention is to provide an osmotic dispenser of simple design which will release active agent solution, or gel, or semisolid active agent formulation, at a controlled rate over a prolonged period of time.
In attaining the objects of this invention, one feature resides in an osmotic dispenser comprised of a first compartment of relatively impervious material containing an active agent and a second compartment containing a solution of an osmotically effective solute which exhibits an osmotic pressure gradient against water. Separating the said first from the said second compartment, and defining a wall member common to each of said compartments, is a sliding or movable barrier of impervious material. The enclosure, whether of integral construction or not, defining the remainder of the second compartment, wherein the osmotic motive force of the dispenser is developed, is at least in part comprised of membrane which exhibits controlled permeability to water. When placed in a hypotonic aqueous environment, water, by osmosis, is absorbed therefrom through the membrane and diffuses into the solution contained in the said second compartment. As the water flows into the second compartment, the solution contained therein increases in volume exerting corresponding pressure behind the movable barrier divider. Such pressure serves to drive the said barrier forward and into the active agent compartment thus diminishing the volume of same and which sliding barrier in turn ejects the active agent out of the apparatus at an osmotically controlled rate over a prolonged period of time. For purposes of permitting the active agent to be squeezed out of the first compartment, same is provided with any suitable dispensing head or active agent release means to the exterior of the device, for example, capillary ducts therethrough.
A further feature of this invention resides in an osmotic active agent dispenser comprised of a plurality of capsule half shells, similar in shape to pharmaceutical hard gelatin half shells, with a first and a second half shell being securedly affixed in capsular configuration, and a third half shell frictionally disposed in such capsule but free to slidably move therein. The said capsule is thereby divided into the two compartments with the third half shell defining the wall member common to each of same. Optionally, a fourth half shell defines capping means for the dispensing head of the capsule.
Other objects, features and advantages of this invention will become more apparent from the following description when taken in conjunction with the accompanying drawings and wherein like reference numerals are used to indicate like or equivalent parts.
BRIEF DESCRIPTION OF THE DRAWINGS In the drawings:
FIG. 1 is a cross-sectional view of an osmotic dispenser of this invention;
FIG. la is a fragmentary cross-sectional view of a modification in the dispensing head of the osmotic dispenser of FIG. 1;
FIG. 1b is a fragmentary cross-sectional view of another modification in the dispensing head of the osmotic dispenser of FIG. 1;
FIG. 2 is a cross-sectional view of another osmotic dispenser of this invention;
FIG. 3 is a cross-sectional view of yet another osmotic dispenser of this invention;
FIG. 4 is a cross-sectional view of still another osmotic dispenser of this invention; and
FIG. 5 is an exploded view of the dispenser of FIG. 4.
DETAILED DESCRIPTION OF THE INVENTION In one embodiment in accordance with this invention as illustrated in FIG. 1 an osmotic dispenser 10 is comprised of a rigid, impervious housing member or plastic shell 12, capsule-shaped and having a thickened rounded end and bored with one or more capillary ducts or openings 14 approximately 0.5 mm in diameter. The open end of the plastic shell 12 is sealed or closed off with a membrane 16 which exhibits controlled permeability to water, advantageously a semipermeable, anisotropic cellulose acetate membrane of the type used in reverse osmosis water desalination. The membrane 16 is backed up by and supported by a stiff water-porous disc 18 which is advantageously cemented in place in the said shell 12 and is fabricated from such materials as, for example,.a ceramic frit. A sliding barrier plug, disc or seal 20, of impermeable barrier material compartmentalizes the shell 12 into an active agent compartment 22 and a compartment 24 wherein the motive force of the dispenser is developed. The said first compartment 22 contains the active agent, advantageously a drug, in a gel, paste or other semisolid state (albeit a solution or concentrated solution of active agent will sometimes suffice), and the active agent, if a drug, is preferably normally carried in an oil phase, such as cocoa butter. The said compartment 24 contains a solution of an osmotically effective solute which exhibits an osmotic pressure gradient against water; and the sliding barrier plug 20 is so constructed as to movably provide and maintain a tight barrier between the active agent phase in the first compartment and the osmotic fluid in the second. Without this tight barrier undesirable contamination could take place. The capillary ducts or active agent release means 14 provide communication from the interior of the compartment 22 to the exterior of the device 10, in this instance the said means being comprised of one or more of said capillary ducts 14 drilled in the thickened rounded end or dispensing head of the said shell 12. The plug 20 is frictionally disposed but is free to move within the device by sliding while at the same time maintaining an impenetrable or contamination preventing barrier between the active agent phase and the osmotic fluid.
To use the osmotic active agent dispenser of FIG. 1, the device, when the active agent is a drug or other agent for treating, etc., a living organism, is either physically inserted or surgically implanted in the body of the organism, typically a mammal, or is administered via the gastrointestinal tract. Once in place, water will be absorbed therein from either body tissues or body fluids through the stiff porous support 18 and through the water permeable membrane 16 in an effort to reach osmotic equilibrium, i.e., a transition from hypertonicity to isotonicity. As the water flows by osmosis into the compartment 24 tending to increase the volume of same corresponding pressure is built up behind the sliding barrier plug 20. Such pressure serves to drive the said barrier plug forward at a constant rate thus forcing the drug through the capillaries 14 at an osmotically controlled and constant rate into the external environment. There is accordingly provided the gradual and controlled constant release of drug or similar agent directly to the body or affected organ thereof over a prolonged period of time. Moreover, the use of any semisolid drug vehicle will reduce the tendency to release the drug, or any other active agent for that matter, by leaching and will permit high concentrations thereof to be embodied within the device.
In some instances, the dispenser is of insufficient specific gravity to maintain placement at the desired location. For example, for use in the rumen of polygastric animals, the weight should be sufficient to provide a specific gravity of at least 1.5. In those instances of insufficient specific gravity, therefore, a weight or ballast can be placed in the device, such as the steel ball 26 of FIG. 1. Other suitable weights comprise iron plugs, iron ore tablets, brass plugs, ceramic plugs, or the like.
When the active agent is other than a drug or similar agent, or is intended for use other than in a living organism, the device is introduced into the desired aqueous environment to produce the desired effect exactly as would be any of the known means for accomplishing a like result. And this is generally a mere physical insertion, such as by placing a pesticide containing device in a river or stream, or a catalyst containing device in an aqueous reaction medium.
If desired, long flexible tubing of polythene or the like can be extended from the dispensing head of the device of FIG. 1. See FIG. la. In such manner the device can be deposited at a site remote from the desired point of application and still release its active agent contents through the dispensing head and then through the tube directly to said point. This permits placement of the dispenser in an aqueous environment and release of the active agent into another environment which need not be aqueous. The dispensing head can also be provided with a check valve, for example, a one way ball valve (see FIG. 1b), to prevent back flow of active agent or other materials from the external environment into the device.
The design of the FIG. 1 device is moreover unique in that it requires a membrane of but limited surface area. This because of the ready availability of the highly water-permeable cellulose acetate membranes designed for use in reverse osmosis processes for water desalination. These membranes, typically and preferably anisotropic membranes, are highly permeable to water (allow relatively rapid rates of water transmission) but are relatively impermeable to salt, thus permitting their use in relatively small exposure area devices.
In FIG. 2 there is depicted an osmotic active agent dispenser 10 which allows for higher available exposure area of the membrane 16 and, accordingly, which design takes advantage of the availability of a far greater number of membranes than the semi-permeable, anisotropic cellulose acetate membranes of the type used in reverse osmosis water desalination. In this embodiment, both the membrane 16 and the stiff water porous support 18 are cup shaped rather than a flat disc, with the former being adhered or cemented to the latter. The designs of both FIG. 1 and FIG. 2 are also such that the porous disc or cup 18/membrane l6 assembly can alternatively merely be snapped or press-fit into the porous shell 12 and be there secured without the need for added adhesive or cement, and in such manner this mechanical lock in and of itself prevents any leakage. Optionally, in another alternative embodiment, a separator of porous paper, fabric or the like can conveniently be disposed between the support 18 and membrane 16. This prevents the membrane from being punctured or drawn into too tight a contact with the casing, thereby assuring that the entire membrane is exposed to the aqueous environment. Also in FIG. 2 it is depicted that the separator 20 may take the configuration of a capsule half shell, rather than a plug or disc (as in, for example, the design of FIG. 3).
FIG. 3 illustrates another embodiment of this invention wherein an osmotic active agent dispenser 30, similar to that of FIG. 1, is comprised of three, and optionally four capsule half shells, similar in shape to pharmaceutical hard gelatin half shells. The shell 32 is optional and designed to rapidly dissolve in the aqueous environment in which the device is intended to be placed, for example, is designed to rapidly dissolve in body fluids (when the active agent is a drug or other agent for treating, etc., a living organism). Shell 32 thus provides a capping means for the release port 44 of the capsule. Contran'wise, the shells 34 and 36 are rigid and resistant to dissolution and degradation in the aqueous environment or body fluids, but exhibit controlled permeability to moisture. The shells 34 and 38 are cemented tightly on manufacture, in capsular configuration, with shell 36 being free to move or slide in response to water flowing into the compartment 40, which compartment contains the solution of the osmotically effective solute exhibiting an osmotic pressure gradient against water, and said compartment 40 being defined by the walls of the said shells 36 and 38 and to some extent by the walls of the said shell 34. The active agent, advantageously a drug, is contained in the compartment 42 which is defined by the space between the walls of the shells 34 and 36. Shell 34 is provided with an aperture or orifice 4-4 from which the active agent or drug exits upon expansion of the solution compartment 40 which forces the shell 36 further into the active agent compartment 42, thus diminishing the active volume of the latter. The shell 36 is frictionally set into the shells 34 and 38 to such an extent (1) that it is free to move in response to absorption of water through the permeable shell 38 and concomitant increase in volume of the said compartment 40 but (2) the fit is tight enough as to prevent commingling and contamination of the contents of the several compartments 40 and 42 by leakage. It can be seen that, in use, as water flows into the solution compartment in a tendency towards osmotic equilibrium with the environment, the said solution compartment expands or increases in volume by forcing the interior shell further into the active agent compartment, thus continuously ejecting or squeezing active agent thereout at an osmotically controlled rate over a prolonged period of time. Thus, it will be appreciated that, mechanism-wise, the dispenser of FIG. 3 is functionally equivalent to those of .FIGS. I and 2. The shell 38 most preferably is a composite comprised of a rigid, highly porous half shell 46 lined with membrane 48 which is controlledly permeable to water. Such composite is readily fabricated by either lining or laminating the membrane 48 to the porous half shell 46, or by casting a film of the said membrane 48 onto and preferably within the said shell 46. The aforementioned casting about the porous shell is advantageously perfected by depositing the film from a solution of membrane forming material in a solvent, e.g., a 20 percent solution of cellulose acetate in an acetone-ethanolethyl lactate mixed solvent, 65 percent 20 percent 15 percent. In casting the film, care should be taken that the pores of the shell 46 do not become clogged.
Moreover, a device of either FIG. 1, FIG. 2 or FIG. 3 type is admirably suited for the continuous administration of the antibiotic oxytetracycline to beef cattle from the rumen. This because such devices can easily be fabricated of a size, weight and shape as to be retained in the rumen of polygastric animals to release drug or similar agent thereto at a carefully controlled rate. Other variations on the basic theme would be readily apparent to the skilled artisan. Although particular configurations may be designed for specific body uses, each of these configurations is applicable to use in other environments.
The membrane 16 of FIGS. 1 and 2 and the half shell lining 48 of FIG. 3 can be formed from a wide variety of materials permeable or semi-permeable to solvent (water) but not to solute, i.e., those suitable for the construction of an osmotic cell. For best results, the membrane should be substantially impermeable to passage of the osmotically effective solute so as to prevent loss thereof. Typical membranes are isotropic membranes such as unplasticized cellulose acetate, plasticized cellulose acetate, reinforced cellulose acetate, cellulose diand triacetate, ethyl cellulose; anisotropic reverse osmosis membranes which typically are made of cellulose acetate; silicone rubbers, polyurethanes, natural rubber, and hydrolyzed ethylene/vinyl acetate copolymers. Isotropic membranes have less water permeability than do the anisotropic membranes. Also, with both types of membranes, increasing the acetate content of the cellulose acetate polymer decreases the water permeability. Since, as previously described, the surface area of the membrane is relatively limited in a device of FIG. 1 type, it will be preferred to use semipermeable membranes allowing relatively rapid water transmission in this general category of dispensers. Thus, in such embodiments the anisotropic membranes are the preferred. A cellulose acetate membrane suitable for this limited surface area application is Eastman Chemical Products Type R 97, which is rated to be permeable to 1.5 to 2 cc/cm /day at atmospheric pressure, against a saturated solution of K 80 at 39 C. A specific example of the design of FIG. 1 constructed with polymethylmethacrylate dispensing head, separator and tubing having an inner diameter of 1.9 cm, is capable of delivering 4 to 6 cc of active agent, advantageously a drug, per day. In one specific embodiment of a dispenser of FIG. 2 type, the membrane used was an isotropic cellulose acetate membrane, with no plasticizer, having an acetate substitution of 2.4, being 3 mils thick, and passing water at the rate of mg/cm per day against a saturated magnesium sulfate solution at 39 C. The membranes too are insoluble, and chemically compatible with the salt solution and any excess solute therein. For drug depot applications as heretofore described, the membranes are also biologically inert, non-irritating to body tissues and non-allergenic. For devices designed to deliver active agents relatively rapidly for a limited period, membranes of controlled high water permeability are indicated; membranes of lower water permeability are used to provide slower and more prolonged delivery.
The impermeable plastic shell 12 of FIGS. 1 and 2 and the half shell 34 of FIG. 3 too are insoluble and can be formed of polystyrene, polyethylene, polypropylene, polyvinyl chloride, reinforced epoxy resin, polymethylmethacrylate, etc., sheet metal (e.g., aluminum, cop per, steel, etc.), galvanized pipe, or styrene/acrylonitrile copolymer. It is of course intended that such casing or shell act as a barrier to the transport of water. Again, for drug depot applications the same are advantageously biologically inert, non-irritating to body tissues and non-allergenic. The barrier plug 20 and the half shell 36 can be formed of materials identical to those used for fabricating the shells 12 and 34. Espe cially preferred of the above are the impermeable or refractory plastics. Likewise with respect to thevporous disc or cup 18 of FIGS. 1 and 2, and the half shell 46 of FIG. 3, except in this instance the materials would be highly porous since it is not intended that the member 18 and the half shell 46 in any way act as a barrier to or restrict the transport of water.
l-Ialf shell 32 of the FIG. 3 dispenser can be formed from any material which will rapidly dissolve in the aqueous environment in which the device is intended to be placed, such as gelatin and such material again being biologically inert, non-irritating to body tissues and non-allergenic when the device is designed for placement in the body.
Many other materials including those which are biologically acceptable are suitable for fabrication of the several component parts of the device of this invention. While the said several component parts of the device of the invention have previously been described as being insoluble under the conditions and in the environment of intended use, it is also within the scope of the invention that such materials be insoluble only during the period of said intended use; thereafter dissolving away in the environment of the device. Thus, a dis penser is here contemplated which is unaffected by its environment, solubility-wise, at the situs of use, or which is only slightly soluble during the period of intended use, such that once its active agent content has been discharged it will then dissolve or erode away leaving no objectionable residue or empty container at the said situs of use.
It is further within the scope of the invention to optionally provide the subject dispenser with a selfcontained water supply or separate water compartment, as in the first mentioned Rose and Nelson publication, supra.
The relative thicknesses of the various membranes comprising the dispensers of the invention, as well as the relative thickness of the various shells and half shells can vary widely and are not limitations on the invention. Typically, however, each shell and half shell has a wall thickness of 0.5 to 50 mils, preferably of 5 to 50 mils, and the water permeable membranes have a wall thickness of 1 to 10 mils.
One specific embodiment of a dispenser fabricated in accordance with the invention, and as illustrated in FIG. 4 and 5, fitted witha 3 mils thick semi-permeable membrane 16, and having the following dimensions and specifications:
Outer diameter of dispenser 1.125 inch Wall thickness of shell 12 0.125 inch Inner diameter of dispenser 0.875 inch Overall length 2.5 inch External volume 2.45 inch lntemal volume 1.24 inch Overall dispenser density 1.5
Available membrane area 0.44 inch Active agent volume 0.94 inch Active agent density 1.2
Active agent: Approximately 60 percent tetracycline hydrochloride dispersed in 40 percent cocoa butter medium;
Osmotic solution: Saturated aqueous solution of K 80 containing sufficient excess solute in solid form to maintain solution saturated over a period of at least 3 days; Water permeable membrane: Cellulose diacetate, with a degree of acetyl substitution of 2.4;
Shell 12: Soft polyethylene; Threaded end cap 50: Soft polyethylene; Delivery cap 52: Soft polyethylene; Barrier member 20: Soft polyethylene; Chamfered ring 54: Polycarbonate; Membrane support 18: Polystyrene; Diameter of delivery port 14: 0.0625 inch; Diameter of orifices in cap 50: 0.0625 inch; Diameter of orifices in support 18: 0.1250 inch; is capable of delivering gm of the active drug per day, over a period of 3 days, when administered to the rumen of a 500 pound calf, whereat it is retained, via the gastrointestinal tract. It will be appreciated that the design of the FIG. 4 and FIG. 5 device is quite similar to that of FIG. 1, with the most salient distinctions therebetween residing, in the FIGS. 4 and 5 device, in the separate rather than integral delivery cap 52; the chamfered polycarbonate retaining ring 54 which aids in maintaining a tight seal between the shell 12 and cap 52; and the perforated end cap construction 50 which is threaded onto the shell 12 and fitted with a rubber O-ring 56 to prevent leakage at the point of the thread fit. The cap 50 houses the membrane 16 and the membrane support 18. Of course, the greater the free space or total open surface area of the plurality of ducts bored into the end cap 50, the greater the amount of the membrane 16 which is exposed to the aqueous environment. Likewise, the greater the open surface area of the plurality of ducts bored into the membrane support 18, the more readily the water difi'uses into the compartment 24. As in the designs of FIGS. 1 and 2, it is again optional that a separator of porous paper, fabric or the like can be placed between either or both of the membrane support 18 and end cap 50 and the semipermeable membrane 16. Same, as heretofore mentioned, prevents the membrane from being punctured or drawn into too tight a contact with its housing, thereby additionally assuring that the entire membrane is exposed to the aqueous environment.
Any of the drugs used to treat the body, both topical and systemic, can be compartmentalized as the active agent in any of the osmotic dispensers of this invention. Drug is used herein in its broadest sense as including any composition of substance that will produce a pharmacological or biological response.
Suitable drugs for use in therapy with the dispenser of the invention include without limitation:
1. Protein drugs such as insulin;
2. Desensitizing agents such as ragweed pollen antigens, hay fever pollen antigens, dust antigen and milk antigen;
3. Vaccines such as small pox, yellow fever, distemper, hog cholera, fowl pox, antivenom, scarlet fever, diphtheria toxoid, tetanus toxoid, pigeon pox, whooping cough, influenza, rabies, mumps, measles, poliomyelitis, Newcastle disease, etc.;
4. Anti-infectives, such as antibiotics, including penicillin, tetracycline, chlortetracycline, bacitracin, nystatin, streptomycin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethizole, sulfamethazine, sulfadiazine, sulfamerazine, and sulfisoxazole; anti-virals including idoxuridine; and other anti-infectives including nitrofurazone and sodium propionate;
5. Anti-allergenics such as antazoline, methapyrilene,
chlorpheniramine, pyrilamine and prophenpyridamine;
6. Anti-inflammatories such as hydrocortisone; cortisone, hydrocortisone acetate, dexamethasone, dexamethasone 2 l-phosphate, fluocinolone, triamcinolone, medrysone, prednisolone, prednisolone 21-phosphate, and prednisolone acetate;
7. Decongestants such as phenylephrine, naphazoline, and tetrahydrozoline;
8. Miotics and anticholinesterases such as pilocarpine, eserine salicylate, carbachol, di-isopropyl fluorophosphate, phospholine iodide, and demecarium bromide;
9. Mydriatics such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, and hydroxy-amphetamine;
10. Sympathomimetics such as epinephrine;
11. Sedatives and Hypnotics such as pentobarbital sodium, phenobarbital, secobarbital sodium, codeine, (a-bromoisovaleryl) urea, carbromal;
l2. Psychic Energizers such as 3-( 2-aminopropyl) indole acetate and 3-(2-aminobutyl) indole acetate;
13. Tranquilizers such as reserpine, chlorpromazine,
and thiopropazate;
14. Androgenic steroids such as methyltestosterone and fluoxymesterone;
15. Estrogens such as estrone, 17 B -estradiol, ethinyl estradiol, and diethyl stilbesterol;
l6. Progestational agents such as progesterone, megestrol, melengestrol, chlormadinone, ethisterone, norethynodrel, l9-nor-progesterone, norethindrone, medroxyprogesterone and l 7 a-hydroxy-progesterone;
17. Humoral agents such as the prostaglandins, for
example, PGE P05 and PGF 18. Antipyretics such as aspirin, sodium salicylate,
and salicylamide;
19. Antispasmodics such as atropine, methantheline,
papaverine, and methscopolamine bromide;
20. Anti-malarials such as the 4-aminoquinolines, 8-
aminoquinolines, chloroquine, and pyrimethamine;
21. Antihistamines such as diphenhydramine, dimenhydrinate, tripelennamine, perphenazine, and carphenazine;
22. Cardioactive agents such as hydrochlorothiazide,
flumethiazide, chlorothiazide, and aminotrate;
23. Nutritional agents such as vitamins, essential amino acids and essential fats;
24. Anti-Parkinsonism agents such as L-dopa, (L-
3,4-dihydroxyphenylalanine);
25. Investigative antihypotensive agents such as dopamine, 4-(2-aminoethyl) pyrocatechol.
Other drugs having the same or different physiological activity as those recited above can be employed in osmotic dispensers within the scope of the present invention; Suitable mixtures of drugs can, of course, be dispensed with equal facility as with single component systems.
Drugs can be in various forms, such as uncharged molecules, components of molecular complexes, or non-irritating pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulphate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc. For acidic drugs, salts of metals, amines, or organic cations (e.g., quaternary ammonium) can be employed. Furthermore, simple derivatives of the drugs (such as ethers, esters, amides, etc.) which have desirable retention and release characteristics but which are easily hydrolyzed by body pH, enzymes, etc., can be employed.
The amount of drug incorporated in the osmotic dispenser varies widely depending on the particular drug, the desired therapeutic effect, and the time span for which it takes the drug to be released. Since a variety of dispensers in a variety of sizes and shapes are intended to provide complete dosage regimes for therapy for a variety of maladies, there is no critical upper limit on the amount of drug incorporated in the dispenser. The lower limit too will depend on the activity of the drug and the time span of its release from the dispenser. Thus it is not practical to define a range for the therapeutically effective amount of drug to be released by the dispenser.
The motive force of the dispenser of this invention depends on the osmotic pressure generated by the solution of the osmotically effective solute contained in the compartments 24 and 40, which solution exhibits an osmotic pressure gradient against water. Said solution is most preferably a saturated aqueous salt solution. To maintain the solution saturated and therefore to achieve a constant osmotic pressure throughout operation of the dispenser, the compartment containing the solution also contains excess solute in solid form. Various osmotically effective solutes can be used. These include magnesium sulphate, magnesium chloride, sodium chloride, potassium sulphate, sodium carbonate, sodium sulphite, sodium sulphate, sodium bicarbonate, potassium acid phthalate, calcium bicarbonate, potassium acid phosphate, raffinose, tartaric acid, succinic acid, calcium succinate, calcium lactate, and magnesium succinate. The excess solid solute can be in the form of dispersed particles or preferably in the form of a pellet. The solution can initially be a solution of the same or of a osmotically effective solute difi'erent than the solid excess solute.
The osmotic dispenser can be fabricated in any con-- venient shape for either physical insertion or implantation in the body, or for administration via the gastrointestinal tract, or for introduction into any desired aqueous environment. Dimensions of the device can thus vary widely and are not of controlling importance. The lower limit of the size of the device is governed by the amount of the particular active agent to be supplied to the aqueous environment to elicit the desired response, as well as by the form the dosage unit takes, for example, in cases of specific body uses, implantate, bolus, IUD, IVD, vaginal ring, uterine capsule for fertility suppression, artificial gland, pessary, prosthesis, suppository, and the like. Likewise with respect to the upper limit on the size of the device. In one specific embodiment, the dispenser can be of such size as to deliver 1 to 2 0c of drug formulation per day and to deliver a total of 5 to 10 cc of drug formulation over a 5 to 10 day period. With alternate choice of slower permeation membranes, the pump can deliver drug more slowly up to and in excess of 1 year. It is preferred that the construction of the several compartments and of the active agent release means be such that the osmotic driving pressure developed is at least 10 times greater than the back pressure generated by the active agent formulation.
Thus, the invention provides, in an osmotic dispenser, a reliable means for releasing effective concentrations of active agent contained therein to the body of a living organism, or to any other aqueous environment, at an osmotically controlled rate and over a prolonged period of time. In addition, prime advantages of the dispenser of the invention are thatit is simple in construction and exhibits all of the practical advantages of the long-term continuous administration of various active agents both to humans, animals, and into other environments, and that the active agent contained therein will not exhibit the tendency to be leached therefrom.
While the invention has been described and illustrated with reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various modifications, changes, omissions, and substitutions can be made without departing from the spirit of the invention. It is intended, therefore, that the invention be limited only by the scope of the following claims.
What is claimed is:
1. An osmotic active agent dispenser, comprised of a plurality of capsule half shells, with a first and a second half shell securedly afiixed in capsular configuration, and a third half shell frictionally disposed in such capsule but free to slidably move therein, the said capsule being thereby divided into two compartments, an active agent compartment containing active agent and provided with release means therefor to the exterior of the dispenser and a second compartment containing a solution of an osmotically effective solute which exhibits an osmotic pressure gradient against water; the shell of the capsule comprising the solution compartment is rigid, resistant and water pervious; the shell of the capsule comprising the active agent compartment is rigid, resistant and water impervious; and the interior half shell is rigid, resistant and water impervious, the open end of which is in communicating relationship with the said second compartment; whereby as water flows by osmosis into the solution compartment in a tendency towards osmotic equilibrium with its environment the said solution compartment expands by forcing the interior shell further into and diminishing the volume of the active agent compartment, thus continuously squeezing active agent thereout at an osmotically controlled rate over a prolonged period of time.
2. The osmotic dispenser as defined by claim 1, further comprising a rapidly soluble fourth half shell capping the active agent release means of the capsule.
3. The osmotic dispenser as defined by claim 1, wherein the active agent is selected from the group consisting of a drug and a bio-affecting composition.
4. The osmotic dispenser as defined by claim 1, wherein the active agent contained therein is in the form of a semisolid formulation.
5. The osmotic dispenser as defined by claim 1, wherein the solution of an osmotically effective solute exhibiting an osmotic pressure gradient against water is a saturated aqueous salt solution.
6. The osmotic dispenser as defined by claim wherein the saturated salt solution contains excess solute in solid form.
7. The osmotic dispenser as defined by claim 1, wherein the said second compartment is comprised of a membrane selected from the group consisting of cellulose acetate, silicone rubber, polyurethane, natural rubber and hydrolyzed ethylene/vinyl acetate copolymet.
8. The osmotic dispenser as defined by claim 7, wherein the membrane is anisotropic.
9. The osmotic dispenser as defined by claim 1, wherein the osmotically effective solute is selected from the group consisting of magnesium sulphate, magnesium chloride, sodium chloride, potassium sulphate, sodium carbonate, sodium sulphite, sodium sulphate, sodium bicarbonate, potassium acid phthalate, calcium bicarbonate, potassium acid phosphate, raffin0se,'tartan'c acid, succinic acid, calcium succinate, calcium lactate and magnesium succinate.
Claims (8)
- 2. The osmotic dispenser as defined by claim 1, further comprising a rapidly soluble fourth half shell capping the active agent release means of the capsule.
- 3. The osmotic dispenser as defined by claim 1, wherein the active agent is selected from the group consisting of a drug and a bio-affecting composition.
- 4. The osmotic dispenser as defined by claim 1, wherein the active agent contained therein is in the form of a semisolid formulation.
- 5. The osmotic dispenser as dEfined by claim 1, wherein the solution of an osmotically effective solute exhibiting an osmotic pressure gradient against water is a saturated aqueous salt solution.
- 6. The osmotic dispenser as defined by claim 5 wherein the saturated salt solution contains excess solute in solid form.
- 7. The osmotic dispenser as defined by claim 1, wherein the said second compartment is comprised of a membrane selected from the group consisting of cellulose acetate, silicone rubber, polyurethane, natural rubber and hydrolyzed ethylene/vinyl acetate copolymer.
- 8. The osmotic dispenser as defined by claim 7, wherein the membrane is anisotropic.
- 9. The osmotic dispenser as defined by claim 1, wherein the osmotically effective solute is selected from the group consisting of magnesium sulphate, magnesium chloride, sodium chloride, potassium sulphate, sodium carbonate, sodium sulphite, sodium sulphate, sodium bicarbonate, potassium acid phthalate, calcium bicarbonate, potassium acid phosphate, raffinose, tartaric acid, succinic acid, calcium succinate, calcium lactate and magnesium succinate.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10613071A | 1971-01-13 | 1971-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3732865A true US3732865A (en) | 1973-05-15 |
Family
ID=22309650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US00106130A Expired - Lifetime US3732865A (en) | 1971-01-13 | 1971-01-13 | Osmotic dispenser |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3732865A (en) |
Cited By (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2201357A1 (en) * | 1971-01-13 | 1972-09-07 | Alza Corp | Osmotic drug delivery device |
| US3880164A (en) * | 1972-05-22 | 1975-04-29 | Alza Corp | Osmotic wound drain |
| US3894538A (en) * | 1972-08-10 | 1975-07-15 | Siemens Ag | Device for supplying medicines |
| US3995631A (en) * | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US4111203A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
| US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
| US4111201A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
| US4136250A (en) * | 1977-07-20 | 1979-01-23 | Ciba-Geigy Corporation | Polysiloxane hydrogels |
| US4177256A (en) * | 1973-04-25 | 1979-12-04 | Alza Corporation | Osmotic bursting drug delivery device |
| US4180073A (en) * | 1977-08-29 | 1979-12-25 | Alza Corporation | Device for delivering drug to biological environment |
| US4203442A (en) * | 1977-08-29 | 1980-05-20 | Alza Corporation | Device for delivering drug to a fluid environment |
| US4207890A (en) * | 1977-01-04 | 1980-06-17 | Mcneilab, Inc. | Drug-dispensing device and method |
| US4210139A (en) * | 1979-01-17 | 1980-07-01 | Alza Corporation | Osmotic device with compartment for governing concentration of agent dispensed from device |
| US4217894A (en) * | 1977-05-13 | 1980-08-19 | Siemens Aktiengesellschaft | Apparatus for supplying medication to the human or animal body |
| US4277582A (en) * | 1978-03-03 | 1981-07-07 | Ciba-Geigy Corporation | Water-insoluble hydrophilic copolymers |
| WO1981001794A1 (en) * | 1979-12-28 | 1981-07-09 | S Ash | System for demand-based administration of insulin |
| US4298003A (en) * | 1980-05-12 | 1981-11-03 | Alza Corporation | System for delivering agent at zero order rate with emerging agent below saturation |
| US4320758A (en) * | 1979-05-07 | 1982-03-23 | Alza Corporation | Osmotically driven fluid dispenser |
| EP0089548A1 (en) * | 1982-03-18 | 1983-09-28 | Merck & Co. Inc. | Osmotic drug delivery system |
| JPS60103959A (en) * | 1983-11-02 | 1985-06-08 | アルザ コ−ポレ−シヨン | Penetratable capsule |
| FR2561628A1 (en) * | 1984-03-21 | 1985-09-27 | Alza Corp | DEVICE FOR DELIVERING SUBSTANCES WITH SEVERAL COMPONENTS OPERATING IN INTEGRATED UNIT SYSTEM |
| US4548990A (en) * | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US4595583A (en) * | 1984-03-19 | 1986-06-17 | Alza Corporation | Delivery system controlled administration of beneficial agent to ruminants |
| US4612186A (en) * | 1984-03-19 | 1986-09-16 | Alza Corporation | Method for establishing blood levels of biocide in animals |
| US4624945A (en) * | 1984-03-19 | 1986-11-25 | Alza Corporation | Dispensing system with means for increasing delivery of beneficial agent from the system |
| US4643731A (en) * | 1985-08-16 | 1987-02-17 | Alza Corporation | Means for providing instant agent from agent dispensing system |
| US4675174A (en) * | 1985-08-16 | 1987-06-23 | Alza Corporation | Veterinary dispenser delivering beneficial agent by gas power generated in situ |
| US4684524A (en) * | 1984-03-19 | 1987-08-04 | Alza Corporation | Rate controlled dispenser for administering beneficial agent |
| US4692336A (en) * | 1984-03-19 | 1987-09-08 | Alza Corporation | Self controlled release device for administering beneficial agent to recipient |
| US4704118A (en) * | 1985-08-16 | 1987-11-03 | Alza Corporation | Ruminant dispensing device with thermo-activated memory |
| US4717718A (en) * | 1985-08-09 | 1988-01-05 | Alza Corporation | Device for the controlled delivery of a beneficial agent |
| US4717566A (en) * | 1984-03-19 | 1988-01-05 | Alza Corporation | Dosage system and method of using same |
| US4717568A (en) * | 1985-08-09 | 1988-01-05 | Alza Corporation | Laminar arrangement for increasing delivery of beneficial agent from dispenser |
| US4723958A (en) * | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
| US4729793A (en) * | 1985-08-09 | 1988-03-08 | Alza Corporation | Composition for manufacturing wall of dispensing device |
| US4772474A (en) * | 1985-08-09 | 1988-09-20 | Alza Corporation | Dispenser with internal arrangement of lamina means for dispensing beneficial agent |
| US4832690A (en) * | 1987-01-23 | 1989-05-23 | Baxter International Inc. | Needle-pierceable cartridge for drug delivery |
| US4844984A (en) * | 1984-03-19 | 1989-07-04 | Alza Corporation | Dispensing system with means for increasing delivery of beneficial agent from the system |
| US4863456A (en) * | 1986-04-30 | 1989-09-05 | Alza Corporation | Dosage form with improved delivery capability |
| US4865598A (en) * | 1985-08-16 | 1989-09-12 | Alza Corporation | Dispensing system for administering beneficial agent |
| US4871544A (en) * | 1985-08-16 | 1989-10-03 | Alza Corporation | Ruminant dispensing device |
| US4872873A (en) * | 1987-12-14 | 1989-10-10 | Merck & Co., Inc. | Controlled release bolus device |
| US4883667A (en) * | 1985-08-16 | 1989-11-28 | Alza Corporation | Process for forming dispensing device |
| US4927633A (en) * | 1984-03-19 | 1990-05-22 | Alza Corporation | Dispenser for delivering drug to livestock |
| EP0373867A1 (en) * | 1988-12-13 | 1990-06-20 | Alza Corporation | Delivery system comprising means for governing fluid ingress into the system |
| US4955881A (en) * | 1985-08-16 | 1990-09-11 | Alza Corporation | Ruminant dispensing device |
| US4960416A (en) * | 1986-04-30 | 1990-10-02 | Alza Corporation | Dosage form with improved delivery capability |
| US4963141A (en) * | 1985-08-16 | 1990-10-16 | Alza Corporation | Dispensing system for administering beneficial agent formulation to ruminants |
| US4966767A (en) * | 1985-08-16 | 1990-10-30 | Alza Corporation | Ruminant dispensing device comprising agent displacement member |
| WO1990012568A1 (en) * | 1989-04-21 | 1990-11-01 | Moskovsky Avtomobilestroitelny Institut (Vtuz-Zil) | Device for controlled dosed feeding of active substances into an operative medium |
| WO1990012567A1 (en) * | 1989-04-21 | 1990-11-01 | Moskovsky Avtomobilestroitelny Institut (Vtuz-Zil) | Device for controlled dosing of active substances into an operative medium |
| US4976966A (en) * | 1988-12-29 | 1990-12-11 | Alza Corporation | Delayed release osmotically driven fluid dispenser |
| US5000957A (en) * | 1984-03-19 | 1991-03-19 | Alza Corporation | Dispenser comprising hydrophilic osmopolymer |
| US5021053A (en) * | 1989-07-14 | 1991-06-04 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| US5030216A (en) * | 1989-12-15 | 1991-07-09 | Alza Corporation | Osmotically driven syringe |
| WO1992000728A1 (en) * | 1990-07-11 | 1992-01-23 | Alza Corporation | Delivery device with a protective sleeve |
| US5098425A (en) * | 1985-08-16 | 1992-03-24 | Alza Corporation | Method of administering a ruminant dispensing device comprising density member dispersed in hydrogel member |
| US5147654A (en) * | 1990-07-23 | 1992-09-15 | Alza Corporation | Oral osmotic device for delivering nicotine |
| US5234694A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Method for increasing feed efficiency in animals |
| US5234693A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
| US5234692A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
| US5238687A (en) * | 1990-07-11 | 1993-08-24 | Alza Corporation | Delivery device with a protective sleeve |
| US5248310A (en) * | 1992-03-27 | 1993-09-28 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| AU645527B2 (en) * | 1990-01-24 | 1994-01-20 | Alza Corporation | Delivery system comprising means for controlling internal pressure |
| US5312390A (en) * | 1992-01-10 | 1994-05-17 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
| US5443459A (en) * | 1991-01-30 | 1995-08-22 | Alza Corporation | Osmotic device for delayed delivery of agent |
| US5474985A (en) * | 1993-12-22 | 1995-12-12 | The Regents Of The University Of California | Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors |
| US5498255A (en) * | 1993-08-17 | 1996-03-12 | Alza Corporation | Osmotic device for protracted pulsatile delivery of agent |
| US5512299A (en) * | 1992-03-30 | 1996-04-30 | Alza Corporation | Method of treating oral inflammatory disease |
| US5540665A (en) * | 1994-01-31 | 1996-07-30 | Alza Corporation | Gas driven dispensing device and gas generating engine therefor |
| US5573776A (en) * | 1992-12-02 | 1996-11-12 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| US5599535A (en) * | 1995-06-07 | 1997-02-04 | Regents Of The University Of California | Methods for the cyto-protection of the trabecular meshwork |
| US5674888A (en) * | 1995-06-07 | 1997-10-07 | University Of California | Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division |
| US5728088A (en) * | 1988-12-13 | 1998-03-17 | Alza Corporation | Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals |
| US5776493A (en) * | 1989-07-14 | 1998-07-07 | Alza Corporation | Oral osmotic device for delivery of nystatin with hydrogel driving member |
| WO1999004768A2 (en) | 1997-07-25 | 1999-02-04 | Alza Corporation | Osmotic delivery system flow modulator apparatus |
| US5879716A (en) * | 1985-12-18 | 1999-03-09 | Advanced Polymer Systems, Inc. | Methods and compositions for topical delivery of benzoyl peroxide |
| US5904935A (en) * | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
| US5938654A (en) * | 1987-06-25 | 1999-08-17 | Alza Corporation | Osmotic device for delayed delivery of agent |
| US5955109A (en) * | 1985-12-18 | 1999-09-21 | Advanced Polymer Systems, Inc. | Methods and compositions for topical delivery of retinoic acid |
| US5997527A (en) * | 1997-03-24 | 1999-12-07 | Alza Corporation | Self adjustable exit port |
| WO2000028976A1 (en) * | 1998-11-16 | 2000-05-25 | A.B. Technologies, L.L.C. | Multi chamber soft capsules and method of making the same |
| US6113938A (en) * | 1997-12-30 | 2000-09-05 | Alza Corporation | Beneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents |
| US6270787B1 (en) | 1997-12-29 | 2001-08-07 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
| US6283953B1 (en) | 1997-12-31 | 2001-09-04 | Alza Corporation | Osmotic drug delivery monitoring system and method |
| US6287295B1 (en) | 1997-07-25 | 2001-09-11 | Alza Corporation | Osmotic delivery system, osmotic delivery system semimpermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
| US20020007173A1 (en) * | 1997-07-10 | 2002-01-17 | Kundig Thomas M. | Method of inducing a CTL response |
| US6361552B1 (en) * | 1998-03-25 | 2002-03-26 | Michael J. Badalamenti | Teething gel applicator with cutter, and burstable ampule and method of making the same |
| US6436091B1 (en) * | 1999-11-16 | 2002-08-20 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
| US6508808B1 (en) | 1999-12-21 | 2003-01-21 | Alza Corporation | Valve for osmotic devices |
| US6544252B1 (en) * | 1998-12-31 | 2003-04-08 | Alza Corporation | Osmotic delivery system having space efficient piston |
| US6575961B2 (en) * | 2001-02-20 | 2003-06-10 | Microlin, L.C. | Fluid delivery device and associated method |
| US20030108590A1 (en) * | 2001-06-22 | 2003-06-12 | Peery John R. | Osmotic implant with membrane and membrane retention means |
| US6629950B1 (en) * | 1998-02-04 | 2003-10-07 | John M. Levin | Fluid delivery system |
| GB2391186A (en) * | 2002-05-28 | 2004-02-04 | John Baker | Dosing device using osmosis to generate internal pressure to expel dosing product |
| US20040039376A1 (en) * | 1996-02-02 | 2004-02-26 | Peery John R. | Sustained delivery of an active agent using an implantable system |
| US6740077B1 (en) * | 1999-02-18 | 2004-05-25 | Alcove Surfaces Gmbh | Implant with permeable element |
| US20040133154A1 (en) * | 1996-10-11 | 2004-07-08 | Flaherty J. Christopher | Systems and methods for delivering drugs to selected locations within the body |
| US20050113746A1 (en) * | 2002-03-27 | 2005-05-26 | Rasoul Sedaghat Kerdar | System for orally administering active substances, vitamins and/or foodstuffs |
| US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
| US20060153844A1 (en) * | 2004-12-29 | 2006-07-13 | Thomas Kundig | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| CN103819007A (en) * | 2014-02-21 | 2014-05-28 | 上海万森水处理有限公司 | Hydrogel driven medicine constant-release apparatus |
| US9138569B2 (en) | 2012-02-29 | 2015-09-22 | SinuSys Corporation | Devices and methods for dilating a paranasal sinus opening and for treating sinusitis |
| US9498239B2 (en) | 2010-08-30 | 2016-11-22 | SinuSys Corporation | Devices and methods for inserting a sinus dilator |
| US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
| US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
| US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| US9682127B2 (en) | 2005-02-03 | 2017-06-20 | Intarcia Therapeutics, Inc. | Osmotic delivery device comprising an insulinotropic peptide and uses thereof |
| US9687263B2 (en) | 2013-05-30 | 2017-06-27 | SinuSys Corporation | Devices and methods for inserting a sinus dilator |
| US9724293B2 (en) | 2003-11-17 | 2017-08-08 | Intarcia Therapeutics, Inc. | Methods of manufacturing viscous liquid pharmaceutical formulations |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| USD835783S1 (en) | 2016-06-02 | 2018-12-11 | Intarcia Therapeutics, Inc. | Implant placement guide |
| US10159714B2 (en) | 2011-02-16 | 2018-12-25 | Intarcia Therapeutics, Inc. | Compositions, devices and methods of use thereof for the treatment of cancers |
| US10231923B2 (en) | 2009-09-28 | 2019-03-19 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| US10501517B2 (en) | 2016-05-16 | 2019-12-10 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
| US10527170B2 (en) | 2006-08-09 | 2020-01-07 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
| US20200155446A1 (en) * | 2018-06-27 | 2020-05-21 | Kashiv Biosciences, Llc | Self-regulating osmotic gastroretentive drug delivery systems |
| US10835580B2 (en) | 2017-01-03 | 2020-11-17 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
| US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
| USD933219S1 (en) | 2018-07-13 | 2021-10-12 | Intarcia Therapeutics, Inc. | Implant removal tool and assembly |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2962023A (en) * | 1955-10-28 | 1960-11-29 | Chappaz Gaston | Medicator |
| US3118439A (en) * | 1957-04-09 | 1964-01-21 | Perrenoud Jean-Pierre | Diagnostic and medicating capsule and the method of use |
| US3247066A (en) * | 1962-09-12 | 1966-04-19 | Parke Davis & Co | Controlled release dosage form containing water-swellable beadlet |
| US3415249A (en) * | 1966-01-07 | 1968-12-10 | Stanley Drug Products Inc | Suppository |
| US3604417A (en) * | 1970-03-31 | 1971-09-14 | Wayne Henry Linkenheimer | Osmotic fluid reservoir for osmotically activated long-term continuous injector device |
-
1971
- 1971-01-13 US US00106130A patent/US3732865A/en not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2962023A (en) * | 1955-10-28 | 1960-11-29 | Chappaz Gaston | Medicator |
| US3118439A (en) * | 1957-04-09 | 1964-01-21 | Perrenoud Jean-Pierre | Diagnostic and medicating capsule and the method of use |
| US3247066A (en) * | 1962-09-12 | 1966-04-19 | Parke Davis & Co | Controlled release dosage form containing water-swellable beadlet |
| US3415249A (en) * | 1966-01-07 | 1968-12-10 | Stanley Drug Products Inc | Suppository |
| US3604417A (en) * | 1970-03-31 | 1971-09-14 | Wayne Henry Linkenheimer | Osmotic fluid reservoir for osmotically activated long-term continuous injector device |
Cited By (191)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3995631A (en) * | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| DE2201357A1 (en) * | 1971-01-13 | 1972-09-07 | Alza Corp | Osmotic drug delivery device |
| US3880164A (en) * | 1972-05-22 | 1975-04-29 | Alza Corp | Osmotic wound drain |
| US3894538A (en) * | 1972-08-10 | 1975-07-15 | Siemens Ag | Device for supplying medicines |
| US4177256A (en) * | 1973-04-25 | 1979-12-04 | Alza Corporation | Osmotic bursting drug delivery device |
| US4111201A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
| US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
| US4111203A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
| US4207890A (en) * | 1977-01-04 | 1980-06-17 | Mcneilab, Inc. | Drug-dispensing device and method |
| US4217894A (en) * | 1977-05-13 | 1980-08-19 | Siemens Aktiengesellschaft | Apparatus for supplying medication to the human or animal body |
| US4136250A (en) * | 1977-07-20 | 1979-01-23 | Ciba-Geigy Corporation | Polysiloxane hydrogels |
| US4180073A (en) * | 1977-08-29 | 1979-12-25 | Alza Corporation | Device for delivering drug to biological environment |
| US4203442A (en) * | 1977-08-29 | 1980-05-20 | Alza Corporation | Device for delivering drug to a fluid environment |
| US4277582A (en) * | 1978-03-03 | 1981-07-07 | Ciba-Geigy Corporation | Water-insoluble hydrophilic copolymers |
| US4210139A (en) * | 1979-01-17 | 1980-07-01 | Alza Corporation | Osmotic device with compartment for governing concentration of agent dispensed from device |
| US4320758A (en) * | 1979-05-07 | 1982-03-23 | Alza Corporation | Osmotically driven fluid dispenser |
| WO1981001794A1 (en) * | 1979-12-28 | 1981-07-09 | S Ash | System for demand-based administration of insulin |
| US4298003A (en) * | 1980-05-12 | 1981-11-03 | Alza Corporation | System for delivering agent at zero order rate with emerging agent below saturation |
| EP0089548A1 (en) * | 1982-03-18 | 1983-09-28 | Merck & Co. Inc. | Osmotic drug delivery system |
| US4548990A (en) * | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| JPS60103959A (en) * | 1983-11-02 | 1985-06-08 | アルザ コ−ポレ−シヨン | Penetratable capsule |
| US4595583A (en) * | 1984-03-19 | 1986-06-17 | Alza Corporation | Delivery system controlled administration of beneficial agent to ruminants |
| US4717566A (en) * | 1984-03-19 | 1988-01-05 | Alza Corporation | Dosage system and method of using same |
| US4612186A (en) * | 1984-03-19 | 1986-09-16 | Alza Corporation | Method for establishing blood levels of biocide in animals |
| US4624945A (en) * | 1984-03-19 | 1986-11-25 | Alza Corporation | Dispensing system with means for increasing delivery of beneficial agent from the system |
| US5000957A (en) * | 1984-03-19 | 1991-03-19 | Alza Corporation | Dispenser comprising hydrophilic osmopolymer |
| US4684524A (en) * | 1984-03-19 | 1987-08-04 | Alza Corporation | Rate controlled dispenser for administering beneficial agent |
| US4692336A (en) * | 1984-03-19 | 1987-09-08 | Alza Corporation | Self controlled release device for administering beneficial agent to recipient |
| US4927633A (en) * | 1984-03-19 | 1990-05-22 | Alza Corporation | Dispenser for delivering drug to livestock |
| US4844984A (en) * | 1984-03-19 | 1989-07-04 | Alza Corporation | Dispensing system with means for increasing delivery of beneficial agent from the system |
| FR2561628A1 (en) * | 1984-03-21 | 1985-09-27 | Alza Corp | DEVICE FOR DELIVERING SUBSTANCES WITH SEVERAL COMPONENTS OPERATING IN INTEGRATED UNIT SYSTEM |
| US4717718A (en) * | 1985-08-09 | 1988-01-05 | Alza Corporation | Device for the controlled delivery of a beneficial agent |
| US4772474A (en) * | 1985-08-09 | 1988-09-20 | Alza Corporation | Dispenser with internal arrangement of lamina means for dispensing beneficial agent |
| US4717568A (en) * | 1985-08-09 | 1988-01-05 | Alza Corporation | Laminar arrangement for increasing delivery of beneficial agent from dispenser |
| US4729793A (en) * | 1985-08-09 | 1988-03-08 | Alza Corporation | Composition for manufacturing wall of dispensing device |
| US4643731A (en) * | 1985-08-16 | 1987-02-17 | Alza Corporation | Means for providing instant agent from agent dispensing system |
| US4966767A (en) * | 1985-08-16 | 1990-10-30 | Alza Corporation | Ruminant dispensing device comprising agent displacement member |
| US5098425A (en) * | 1985-08-16 | 1992-03-24 | Alza Corporation | Method of administering a ruminant dispensing device comprising density member dispersed in hydrogel member |
| US4675174A (en) * | 1985-08-16 | 1987-06-23 | Alza Corporation | Veterinary dispenser delivering beneficial agent by gas power generated in situ |
| US4865598A (en) * | 1985-08-16 | 1989-09-12 | Alza Corporation | Dispensing system for administering beneficial agent |
| US4871544A (en) * | 1985-08-16 | 1989-10-03 | Alza Corporation | Ruminant dispensing device |
| US4963141A (en) * | 1985-08-16 | 1990-10-16 | Alza Corporation | Dispensing system for administering beneficial agent formulation to ruminants |
| US4883667A (en) * | 1985-08-16 | 1989-11-28 | Alza Corporation | Process for forming dispensing device |
| US4704118A (en) * | 1985-08-16 | 1987-11-03 | Alza Corporation | Ruminant dispensing device with thermo-activated memory |
| US4955881A (en) * | 1985-08-16 | 1990-09-11 | Alza Corporation | Ruminant dispensing device |
| US5879716A (en) * | 1985-12-18 | 1999-03-09 | Advanced Polymer Systems, Inc. | Methods and compositions for topical delivery of benzoyl peroxide |
| US5955109A (en) * | 1985-12-18 | 1999-09-21 | Advanced Polymer Systems, Inc. | Methods and compositions for topical delivery of retinoic acid |
| US4960416A (en) * | 1986-04-30 | 1990-10-02 | Alza Corporation | Dosage form with improved delivery capability |
| US4863456A (en) * | 1986-04-30 | 1989-09-05 | Alza Corporation | Dosage form with improved delivery capability |
| US4723958A (en) * | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
| US4832690A (en) * | 1987-01-23 | 1989-05-23 | Baxter International Inc. | Needle-pierceable cartridge for drug delivery |
| US5938654A (en) * | 1987-06-25 | 1999-08-17 | Alza Corporation | Osmotic device for delayed delivery of agent |
| US4872873A (en) * | 1987-12-14 | 1989-10-10 | Merck & Co., Inc. | Controlled release bolus device |
| US5728088A (en) * | 1988-12-13 | 1998-03-17 | Alza Corporation | Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals |
| US6180129B1 (en) * | 1988-12-13 | 2001-01-30 | Alza Corporation | Polyurethane-containing delivery systems |
| US5980509A (en) * | 1988-12-13 | 1999-11-09 | Alza Corporation | Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals |
| EP0373867A1 (en) * | 1988-12-13 | 1990-06-20 | Alza Corporation | Delivery system comprising means for governing fluid ingress into the system |
| AU633514B2 (en) * | 1988-12-13 | 1993-02-04 | Alza Corporation | Delivery system comprising means for governing fluid ingress into the system |
| US4976966A (en) * | 1988-12-29 | 1990-12-11 | Alza Corporation | Delayed release osmotically driven fluid dispenser |
| WO1990012567A1 (en) * | 1989-04-21 | 1990-11-01 | Moskovsky Avtomobilestroitelny Institut (Vtuz-Zil) | Device for controlled dosing of active substances into an operative medium |
| WO1990012568A1 (en) * | 1989-04-21 | 1990-11-01 | Moskovsky Avtomobilestroitelny Institut (Vtuz-Zil) | Device for controlled dosed feeding of active substances into an operative medium |
| US5053032A (en) * | 1989-07-14 | 1991-10-01 | Barclay Brian L | Method of signalling a patient during buccal agent delivery |
| US5869096A (en) * | 1989-07-14 | 1999-02-09 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| US5776493A (en) * | 1989-07-14 | 1998-07-07 | Alza Corporation | Oral osmotic device for delivery of nystatin with hydrogel driving member |
| US5021053A (en) * | 1989-07-14 | 1991-06-04 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| US5030216A (en) * | 1989-12-15 | 1991-07-09 | Alza Corporation | Osmotically driven syringe |
| AU645527B2 (en) * | 1990-01-24 | 1994-01-20 | Alza Corporation | Delivery system comprising means for controlling internal pressure |
| AU655733B2 (en) * | 1990-01-24 | 1995-01-05 | Alza Corporation | Delivery system comprising means for controlling internal pressure |
| WO1992000728A1 (en) * | 1990-07-11 | 1992-01-23 | Alza Corporation | Delivery device with a protective sleeve |
| US5180591A (en) * | 1990-07-11 | 1993-01-19 | Alza Corporation | Delivery device with a protective sleeve |
| US5234692A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
| US5238687A (en) * | 1990-07-11 | 1993-08-24 | Alza Corporation | Delivery device with a protective sleeve |
| US5234694A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Method for increasing feed efficiency in animals |
| US5234693A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
| US5147654A (en) * | 1990-07-23 | 1992-09-15 | Alza Corporation | Oral osmotic device for delivering nicotine |
| US5443459A (en) * | 1991-01-30 | 1995-08-22 | Alza Corporation | Osmotic device for delayed delivery of agent |
| US5312390A (en) * | 1992-01-10 | 1994-05-17 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
| US5248310A (en) * | 1992-03-27 | 1993-09-28 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| US5512299A (en) * | 1992-03-30 | 1996-04-30 | Alza Corporation | Method of treating oral inflammatory disease |
| US5573776A (en) * | 1992-12-02 | 1996-11-12 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| US5498255A (en) * | 1993-08-17 | 1996-03-12 | Alza Corporation | Osmotic device for protracted pulsatile delivery of agent |
| US5474985A (en) * | 1993-12-22 | 1995-12-12 | The Regents Of The University Of California | Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors |
| US5540665A (en) * | 1994-01-31 | 1996-07-30 | Alza Corporation | Gas driven dispensing device and gas generating engine therefor |
| US5904935A (en) * | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
| US5674888A (en) * | 1995-06-07 | 1997-10-07 | University Of California | Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division |
| US5599535A (en) * | 1995-06-07 | 1997-02-04 | Regents Of The University Of California | Methods for the cyto-protection of the trabecular meshwork |
| US5972370A (en) * | 1995-06-07 | 1999-10-26 | Alza Corporation | Peptide/protein suspending formulations |
| US8083708B2 (en) | 1995-10-13 | 2011-12-27 | Medtronic Vascular, Inc. | Systems and methods for delivering drugs to selected locations within the body |
| US20100324471A1 (en) * | 1995-10-13 | 2010-12-23 | Medtronic Vascular, Inc. | Systems and Methods for Delivering Drugs to Selected Locations Within the Body |
| US20070021730A1 (en) * | 1995-10-13 | 2007-01-25 | Medtronic Vascular, Inc. | Systems and Methods for Delivering Drugs to Selected Locations Within the Body |
| US7670329B2 (en) | 1995-10-13 | 2010-03-02 | Medtronic Vascular, Inc. | Systems and methods for delivering drugs to selected locations within the body |
| US8298562B2 (en) | 1996-02-02 | 2012-10-30 | Intarcia Therapeutics, Inc. | Sustained delivery of an active agent using an implantable system |
| US7655257B2 (en) | 1996-02-02 | 2010-02-02 | Intarcia Therapeutics, Inc. | Sustained delivery of an active agent using an implantable system |
| US8080259B2 (en) | 1996-02-02 | 2011-12-20 | Intarcia Therapeutics, Inc. | Sustained delivery of an active agent using an implantable system |
| US20110230865A1 (en) * | 1996-02-02 | 2011-09-22 | Intarcia Therapeutics, Inc. | Sustained delivery of an active agent using an implantable system |
| US20100114074A1 (en) * | 1996-02-02 | 2010-05-06 | Intarcia Therapeutics, Inc. | Sustained delivery of an active agent using an implantable system |
| US8535701B2 (en) | 1996-02-02 | 2013-09-17 | Intarcia Therapeutics, Inc. | Sustained delivery of an active agent using an implantable system |
| US20040039376A1 (en) * | 1996-02-02 | 2004-02-26 | Peery John R. | Sustained delivery of an active agent using an implantable system |
| US20040133154A1 (en) * | 1996-10-11 | 2004-07-08 | Flaherty J. Christopher | Systems and methods for delivering drugs to selected locations within the body |
| US7094230B2 (en) * | 1996-10-11 | 2006-08-22 | Medtronic Vascular, Inc. | Systems and methods for delivering drugs to selected locations within the body |
| JP2002513414A (en) * | 1997-03-24 | 2002-05-08 | アルザ・コーポレイション | Implantable delivery device with self-adjustable outlet port |
| US6217906B1 (en) | 1997-03-24 | 2001-04-17 | Alza Corporation | Self adjustable exit port |
| US5997527A (en) * | 1997-03-24 | 1999-12-07 | Alza Corporation | Self adjustable exit port |
| US20020007173A1 (en) * | 1997-07-10 | 2002-01-17 | Kundig Thomas M. | Method of inducing a CTL response |
| US20090035252A1 (en) * | 1997-07-10 | 2009-02-05 | Kundig Thomas M | Method of inducing a CTL response |
| US7364729B2 (en) | 1997-07-10 | 2008-04-29 | Mannkind Corporation | Method of inducing a CTL response |
| US8372393B2 (en) | 1997-07-10 | 2013-02-12 | Mannkind Corporation | Method of inducing a CTL response |
| US20060153858A1 (en) * | 1997-07-10 | 2006-07-13 | Kundig Thomas M | Method of inducing a CTL response |
| US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
| US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US20010027311A1 (en) * | 1997-07-25 | 2001-10-04 | Guohua Chen | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
| US6287295B1 (en) | 1997-07-25 | 2001-09-11 | Alza Corporation | Osmotic delivery system, osmotic delivery system semimpermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
| WO1999004768A2 (en) | 1997-07-25 | 1999-02-04 | Alza Corporation | Osmotic delivery system flow modulator apparatus |
| US20080071253A1 (en) * | 1997-07-25 | 2008-03-20 | Alza Corporation | Osmotic Delivery System Flow Modulator Apparatus and Method |
| US20050281877A1 (en) * | 1997-07-25 | 2005-12-22 | Guohua Chen | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
| US6840931B2 (en) | 1997-07-25 | 2005-01-11 | Alza Corporation | Osmotic delivery system flow modulator apparatus and method |
| US7407500B2 (en) | 1997-07-25 | 2008-08-05 | Alza Corporation | Osmotic delivery system flow modulator apparatus and method |
| US6923800B2 (en) | 1997-07-25 | 2005-08-02 | Alza Corporation | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
| US20050131389A1 (en) * | 1997-07-25 | 2005-06-16 | Peterson Lewis L. | Osmotic delivery system flow modulator apparatus and method |
| US20030114837A1 (en) * | 1997-07-25 | 2003-06-19 | Peterson Lewis L. | Osmotic delivery system flow modulator apparatus and method |
| US6524305B1 (en) | 1997-07-25 | 2003-02-25 | Alza Corporation | Osmotic delivery system flow modulator apparatus and method |
| US6899887B2 (en) | 1997-12-29 | 2005-05-31 | Micron Technology, Inc. | Osmotic delivery system with membrane plug retention mechanism |
| US6270787B1 (en) | 1997-12-29 | 2001-08-07 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
| US6976981B2 (en) | 1997-12-29 | 2005-12-20 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
| US20050048097A1 (en) * | 1997-12-29 | 2005-03-03 | Rupal Ayer | Osmotic delivery system with membrane plug retention mechanism |
| US20040243106A1 (en) * | 1997-12-29 | 2004-12-02 | Rupal Ayer | Osmotic delivery device with membrane plug retention mechanism |
| US6113938A (en) * | 1997-12-30 | 2000-09-05 | Alza Corporation | Beneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents |
| US6283953B1 (en) | 1997-12-31 | 2001-09-04 | Alza Corporation | Osmotic drug delivery monitoring system and method |
| US6629950B1 (en) * | 1998-02-04 | 2003-10-07 | John M. Levin | Fluid delivery system |
| US8540694B2 (en) | 1998-03-25 | 2013-09-24 | Medtronic Vascular, Inc. | Systems and methods for delivering drugs to selected locations within the body |
| US6361552B1 (en) * | 1998-03-25 | 2002-03-26 | Michael J. Badalamenti | Teething gel applicator with cutter, and burstable ampule and method of making the same |
| WO2000028976A1 (en) * | 1998-11-16 | 2000-05-25 | A.B. Technologies, L.L.C. | Multi chamber soft capsules and method of making the same |
| US20060129139A1 (en) * | 1998-12-31 | 2006-06-15 | Felix Theeuwes | Osmotic delivery system having space efficient piston |
| US6872201B2 (en) | 1998-12-31 | 2005-03-29 | Bonnie Burdett Dennis | Osmotic delivery system having space efficient piston |
| US20050085797A1 (en) * | 1998-12-31 | 2005-04-21 | Felix Theeuwes | Osmotic delivery system having space efficient piston |
| US7235068B2 (en) | 1998-12-31 | 2007-06-26 | Alza Corporation | Osmotic delivery system having space-efficient piston |
| US20070203476A1 (en) * | 1998-12-31 | 2007-08-30 | Alza Corporation | Osmotic Delivery System Having Space Efficient Piston |
| US6997922B2 (en) | 1998-12-31 | 2006-02-14 | Alza Corporation | Osmotic delivery system having space efficient piston |
| US6544252B1 (en) * | 1998-12-31 | 2003-04-08 | Alza Corporation | Osmotic delivery system having space efficient piston |
| US6740077B1 (en) * | 1999-02-18 | 2004-05-25 | Alcove Surfaces Gmbh | Implant with permeable element |
| US20040111080A1 (en) * | 1999-11-16 | 2004-06-10 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
| US6436091B1 (en) * | 1999-11-16 | 2002-08-20 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
| US6508808B1 (en) | 1999-12-21 | 2003-01-21 | Alza Corporation | Valve for osmotic devices |
| US6682522B2 (en) | 1999-12-21 | 2004-01-27 | Alza Corporation | Valve for osmotic devices |
| US6575961B2 (en) * | 2001-02-20 | 2003-06-10 | Microlin, L.C. | Fluid delivery device and associated method |
| AU2002255567B2 (en) * | 2001-02-20 | 2005-06-09 | Microlin, L.C. | Fluid delivery device and associated method |
| AU2002315374B2 (en) * | 2001-06-22 | 2008-07-24 | Intarcia Therapeutics, Inc. | Osmotic implant with membrane and membrane retention means |
| US20070087058A1 (en) * | 2001-06-22 | 2007-04-19 | Peery John R | Osmotic implant with membrane and membrane retention means |
| US20030108590A1 (en) * | 2001-06-22 | 2003-06-12 | Peery John R. | Osmotic implant with membrane and membrane retention means |
| US7163688B2 (en) * | 2001-06-22 | 2007-01-16 | Alza Corporation | Osmotic implant with membrane and membrane retention means |
| US20050113746A1 (en) * | 2002-03-27 | 2005-05-26 | Rasoul Sedaghat Kerdar | System for orally administering active substances, vitamins and/or foodstuffs |
| GB2391186B (en) * | 2002-05-28 | 2004-11-03 | John Baker | Controlled dosing device for toilet flush water or other applications |
| GB2391186A (en) * | 2002-05-28 | 2004-02-04 | John Baker | Dosing device using osmosis to generate internal pressure to expel dosing product |
| US9724293B2 (en) | 2003-11-17 | 2017-08-08 | Intarcia Therapeutics, Inc. | Methods of manufacturing viscous liquid pharmaceutical formulations |
| US20060153844A1 (en) * | 2004-12-29 | 2006-07-13 | Thomas Kundig | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
| US10363287B2 (en) | 2005-02-03 | 2019-07-30 | Intarcia Therapeutics, Inc. | Method of manufacturing an osmotic delivery device |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| US9682127B2 (en) | 2005-02-03 | 2017-06-20 | Intarcia Therapeutics, Inc. | Osmotic delivery device comprising an insulinotropic peptide and uses thereof |
| US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
| US10527170B2 (en) | 2006-08-09 | 2020-01-07 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
| US10441528B2 (en) | 2008-02-13 | 2019-10-15 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| US10869830B2 (en) | 2009-09-28 | 2020-12-22 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
| US10231923B2 (en) | 2009-09-28 | 2019-03-19 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
| US12042557B2 (en) | 2009-09-28 | 2024-07-23 | I2O Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
| US9629644B2 (en) | 2010-08-30 | 2017-04-25 | SinuSys Corporation | Devices and methods for dilating a paranasal sinus opening and for treating sinusitis |
| US9498239B2 (en) | 2010-08-30 | 2016-11-22 | SinuSys Corporation | Devices and methods for inserting a sinus dilator |
| US10159714B2 (en) | 2011-02-16 | 2018-12-25 | Intarcia Therapeutics, Inc. | Compositions, devices and methods of use thereof for the treatment of cancers |
| US9504812B2 (en) | 2012-02-29 | 2016-11-29 | SinuSys Corporation | Devices and methods for dilating a paranasal sinus opening and for treating sinusitis |
| US9149616B2 (en) | 2012-02-29 | 2015-10-06 | SinuSys Corporation | Devices and methods for dilating a paranasal sinus opening and for treating sinusitis |
| US9138569B2 (en) | 2012-02-29 | 2015-09-22 | SinuSys Corporation | Devices and methods for dilating a paranasal sinus opening and for treating sinusitis |
| US9597485B2 (en) | 2012-02-29 | 2017-03-21 | SinuSys Corporation | Devices and methods for dilating a paranasal sinus opening and for treating sinusitis |
| US9687263B2 (en) | 2013-05-30 | 2017-06-27 | SinuSys Corporation | Devices and methods for inserting a sinus dilator |
| CN103819007A (en) * | 2014-02-21 | 2014-05-28 | 上海万森水处理有限公司 | Hydrogel driven medicine constant-release apparatus |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| US10583080B2 (en) | 2014-09-30 | 2020-03-10 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
| US10501517B2 (en) | 2016-05-16 | 2019-12-10 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
| US11840559B2 (en) | 2016-05-16 | 2023-12-12 | I2O Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
| US11214607B2 (en) | 2016-05-16 | 2022-01-04 | Intarcia Therapeutics Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
| USD962433S1 (en) | 2016-06-02 | 2022-08-30 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD912249S1 (en) | 2016-06-02 | 2021-03-02 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD835783S1 (en) | 2016-06-02 | 2018-12-11 | Intarcia Therapeutics, Inc. | Implant placement guide |
| US10835580B2 (en) | 2017-01-03 | 2020-11-17 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
| US11654183B2 (en) | 2017-01-03 | 2023-05-23 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of exenatide and co-administration of a drug |
| US20200155446A1 (en) * | 2018-06-27 | 2020-05-21 | Kashiv Biosciences, Llc | Self-regulating osmotic gastroretentive drug delivery systems |
| US10744083B2 (en) * | 2018-06-27 | 2020-08-18 | Kashiv Biosciences, Llc | Self-regulating osmotic gastroretentive drug delivery systems |
| USD933219S1 (en) | 2018-07-13 | 2021-10-12 | Intarcia Therapeutics, Inc. | Implant removal tool and assembly |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3732865A (en) | Osmotic dispenser | |
| US3760805A (en) | Osmotic dispenser with collapsible supply container | |
| US3995631A (en) | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient | |
| US4034756A (en) | Osmotically driven fluid dispenser | |
| US3760806A (en) | Helical osmotic dispenser with non-planar membrane | |
| US3760804A (en) | Improved osmotic dispenser employing magnesium sulphate and magnesium chloride | |
| US3995632A (en) | Osmotic dispenser | |
| US3929132A (en) | Osmotic dispenser | |
| US3916899A (en) | Osmotic dispensing device with maximum and minimum sizes for the passageway | |
| US3760984A (en) | Osmotically powered agent dispensing device with filling means | |
| EP0266929B1 (en) | Stressed polymeric device for controlled release of a substance to an ambient environment | |
| US4601893A (en) | Laminate device for controlled and prolonged release of substances to an ambient environment and method of use | |
| CA2032923C (en) | Long-term delivery device including loading dose | |
| US3995634A (en) | Vaginal cavity dispensing means and method | |
| US3840009A (en) | Self-powered vapor pressure delivery device | |
| US4142526A (en) | Osmotic releasing system with means for changing release therefrom | |
| US3845770A (en) | Osmatic dispensing device for releasing beneficial agent | |
| US4067961A (en) | Controlled release article | |
| JPS62283918A (en) | Pulse type drug releasing system | |
| GB1565678A (en) | Implatable vaginal medicament dispenser | |
| GB1565677A (en) | Implantable vaginal medicament dispenser | |
| JP2659932B2 (en) | Transdermal and transmucosal drug applicators | |
| EP0153070B1 (en) | Laminate device for controlled and prolonged release of substances to an ambient environment | |
| JPS6210205B2 (en) | ||
| US3796217A (en) | Drug release system |